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CYP82E4v2 MLSPIEAIVG LVTFTFLFmF LWTKKSQKPS KPLPPKIPGG ~i/PVIGHLFHF 
CYP82E4v6 MLSPIEAIVG LVTFTFLFEF LWTKKSQKPS KPLPPKIPGG ~i/PVIGHLFHF 
CYP82E4v12 MLSPIEAIVG LVTFTFLFEF LWTKKSQKPS KPLPPKIPGG ~i/PVIGHLFHF 
58-166 MVEPIEAIVG LVTFTFLFYF LWTKKSQKPS KPLPPKIPGG ~i/PVIGHLFHF 
CYP82E3 MYJfPVEA~VG LVTFTFLFYF LWTKKSQKPS KPLPPKIPGG ~i/PVI GHLF:XF 
CYP82E2v1 MVEPIEAE)VG LVTFTFLflYF LWTKKSQK@:Jli KPLPPKIPGG ~i/PVIGHLFHF 
CYP82E2v2 MLSPIEAFVG LVTFTFL$YF ~~~~i6i!~ KPLPPKIPGG ~i/PVIGHLFHF CYP82E5v2 MVSPMEAiVG KPLPPKIPGG ~i/PVI GHLFj:F 
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CYP82E4v2 NDDGDDRPLI>. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AVKDCFSTND 
CYP82E4v6 NDDGDDRPLI>. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AVKDCFSTND 
CYP82E4v12 NDDGDDRPLA RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AVKDCFSTND 
58-166 NDDGNDRPLF. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE A!KDCFSTND 
CYP82E3 DDDGDDRPLI>. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AlKDCFSTND 
CYP82E2v1 NNDGDDRPLF. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AlKDCFSTND 
CYP82E2v2 "tJ.NDGDDRPLA RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AJKDCFSTND 
CYP82E5v2 [pDDGDDRPLI>. RKLGDLADKY GPVFTFRLGL PLVLVVSSYE AVKDCFSTND 
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CYP82E4v2 l>.IFSNRPAFL YGDYLGYNNA 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRLEK 
CYP82E4v6 l>.IFSNRPAFL YGDYLGYNNA 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRLEK 
CYP82E4v12 l>.IFSNRPAFL YGijYLGYNNA 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRLEK 
58-166 l>.IFSNRPAFL YGEYLGYNNA 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRL:@K 
CYP82E3 l>.IFSNRPAFL YGEYLGYXN:!\ 1'1LFLANYG$Y WRKNRKLjiQ EVLSI>.SRLEK 
CYP82E2v1 l>.IFSNRPAFL YGEYLGYNN$ 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRLEK 
CYP82E2v2 l>.IFSNRPA:ijL YGEYLGYNNl 1'1LFLANYGPY WRKNRKLVIQ EVLSI>.SRLEK 
CYP82E5v2 l>.IFSNRPAFL YGEYLGYSNA 1'1LFL$:@YGPY WRKNRKLVIQ EVLSI>.SRLEK 
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CYP82E4v2 FKHVRFARIQ ASIKNLYTRI DGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E4v6 FKHVRFARIQ ASIKNLYTRI DGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E4v12 FKHVRFARIQ $-SIKNLYTRI DGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
58-166 FKHVRFARIQ TSIKNLYTRI DSNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E3 FKHVRFARIQ TSIKNLYTRI DGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E2v1 FKQVRF$RIQ TSIKNLYTRI lJiiGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E2v2 FKQVRF$RIQ TSIKNLYTRI WGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
CYP82E5v2 ji;KHVRF@~IQ TSIK$LYTRI DGNSSTINLT DWLEELNFGL IVKI'1IAGKNY 
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ESGKGDEQVE RFKKAFKDFM ILSI\1EFVLWD AFPIPLFKWV DFQGHVKAMK 
ESGKGDEQVE RFKKAFKDFM ILSI\1EFVLWD AFPIPLFK\I'JV DFQGHVKAMK 
ESGKGDEQVE RFKKAFKDFM ILSI\1EFVLWD AFPIPLFK\I'JV DFQGHVKAMK 
ESGKGDEQVE RFKKAFKDFM I$SI\1EFVLWD AFPIPLFK\I'JV DFQGHVKAMK 
ESGKGDEQVE RFKKAFKDFM ILSI\1EFVLWD AFPIPLFK\I'JV DFQGHVKAMK 
ESGKGDEQVE RFK~tAFKDFM VLSI\1EFVLWD AFPIPLFK\I'JV DFQGHJKAMK 
ESGKGDEQVE RFKNAFKDFM YLSI\1EFVLWD AFPIPLFK\I'JV DFQGHIKAMK 
ESGKGDEQVE RFEKAFKDFJ ILSI\1EFVLWD AFPIPLFK\I'JV DFQGHVKAMK 
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RTFKDIDSVF QNTI\fLEEHINK REK. JVIEVNAE GNEQDFIDVV LSKMSNEYLG 
RTFKDIDSVF QNWLEEHINK REK. JVIEVNAE GNEQDFIDVV LSKMSNEYLG 
RTFKDIDSVF QNWLEEHINK REK. JVIEVNAE GNEQDFIDVV LSKMSNEYLG 
RTFKDIDSVF QNWLEEHINK REK. JVIEVNAE GNEQDFIDVV LSKMSNEYLG 
RTFKDIDSVF QNTI\fLEEHI:\itK REKlJVIEVGTE GNEQDFIDVV LSKMSNEYLG 
RTFKDIDSVF QNTIITLEEHINK REK:JVIEVGAE GNEQDFIDVV LSKlllSKEYLD 
RTFKDIDSVF QNTI\fLEEHINK REK.IEVGAE GNEQDFIDVV LSKll)s:!S:EYLQ 
RTFKDIDSVF QNTI\fLEEH],{ijK REK. JVIEVNAQ GNEQDFIDVV LSKMSNEYLQ 
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EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINW GMALLINNQ:t{ AL$KAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINW GMALLINNQK ALTKAQEEID 
EGYSRDTVIlll l\TVFSLVLDl\ l\.DTVALHINW GMALLINNQ:ij ALWKAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINW GMALLINNQN ALKKAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINQ GMALLINNQN ALKKAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINW GM$LLINNQN ALJlilKAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHINW GMTLLINNQN AL@KAQEEID 
EGYSRDTVIK l\TVFSLVLDl\ l\.DTVALHMNW GMALLINNQl ALKKAQEEID 
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TKVGKDRloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENVEDCVVSG 
TKVGKDRloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENVEDCVVSG 
TKVCKDRloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENVEDCVVSG 
T:i)VGKDRloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENlEDCVVSG 
TKVGKDRloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENVEDCVVSG 
TKVGKDRloJVE ESDIKDLVYL QAIVKKVLRL YPPGPLLVPH ENV]\tDCVVSG 
TKVGKDRloJVE ESDIKDLVYL QAIVK$:VLRL YPPGPLLVPH ENVlilDCVVSG 
mKVGKERloJVE ESDIKDLVYL QAIVKEVLRL YPPGPLLVPH ENVEDCVVSG 
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YHIPKGTRLF li.NVI\1KLQRDP KL'IIfSPPDTFD PERFLZI.TDID FRGQXYKYIP 
YHIPKGTRLF "Z\NVI\1KL~RDP KL'IITPDPDTFD PERFLZ\TDID FRGQ)tYKYIP 
YHIPKGTRLF "ZI.NVI\1KLQRDP KL'IIfSUPDtFD PERFLZI.TDID FRGQ(~tyjhrP 
Y)i:I$.KGTRLF "Z\NVI\1KLQRDP KLTiffiNPDNFD PERF"iLZIJAGID FRGQHYEYIP 
YHIPKGTRLF "ZI.NVI\1KLQRDP KLTIITSNPDKFN PERFiP,gDID FEGQHYEYIP 
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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional ofU.S. application Ser. No. 
12/269,531, filed Nov. 12, 2008 (issued as U.S. Pat. No. 
8,124,851 on Feb. 28, 2012), which claims the benefit ofU.S. 
Provisional Application No. 60/987,243, filed Nov. 12, 2007, 
the contents of which are hereby incorporated in their entirety 
by reference herein. 
REFERENCE TO SEQUENCE LISTING 
SUBMITTED ELECTRONICALLY 
An official copy of the Sequence Listing is submitted elec-
tronically via EFS-Web as an ASCII formatted Sequence 
Listing with a file named "414656SEQLIST.txt," created on 
Jan. 30, 2012, and having a size of 136 kb and is filed con-
currently with the specification. The Sequence Listing con-
tained in this ASCII formatted document is part of the speci-
fication and is herein incorporated by reference in its entirety. 
FIELD OF THE INVENTION 
The present invention relates to compositions and methods 
for reducing the level of nornicotine and its metabolite, N'-ni-
trosonornicotine (NNN), in a plant that is a member of the 
genus Nicotiana, particularly compositions and methods for 
inhibiting expression or function of a cytochrome P450 
polypeptide involved in the metabolic conversion of nicotine 
to nornicotine. 
BACKGROUND OF THE INVENTION 
A predominant alkaloid found in commercial tobacco vari-
eties is nicotine, typically accounting for 90%-95% of the 
total alkaloid pool. The remaining alkaloid fraction is prima-
rily three additional pyridine alkaloids: nornicotine, ana-
basine and anatabine. Nornicotine is generated directly from 
nicotine by nicotine N -demethylase. Nornicotine usually rep-
resents less than 5% of the total pyridine alkaloid pool. How-
ever, tobacco plants that initially produce very low amounts 
of nornicotine can give rise to progeny that metabolically 
"convert" a large percentage of leaf nicotine to nornicotine. 
This process is termed "conversion." In tobacco plants that 
have genetically converted (i.e., "converters"), the great 
majority of nornicotine production occurs during senescence 
and curing of a mature leaf (Wernsman & Matzinger (1968) 
To b. Sci. 12:226-228). Burley tobaccos are particularly prone 
to genetic conversion, with rates as high as 20% per genera-
tion observed in some cultivars. 
During curing and processing of the tobacco leaf, a portion 
of the nornicotine is metabolized to NNN, a tobacco-specific 
nitrosamine (TSNA) alleged to be carcinogenic in laboratory 
animals (Hecht & Hoffmann (1990) Cancer Surveys 8:273-
294; and Hoffmann eta!. (1994) J. Toxicol. Environ. Health 
41:1-52; Hecht (1998) Chern. Res. Toxicol. 11:559-603). In 
flue-cured tobaccos, TSNAs predominantly form through a 
reaction of alkaloids with minute amounts of nitrogen oxides 
present in combustion gases in a direct-fired heating systems 
used in traditional curing barns (Peele & Gentry (1999) "For-
mation of tobacco-specific nitrosamines in flue-cured 
tobacco," CORESTA Meeting, Agro-Phyto Groups, Suzhou, 
China). The combustion gases, however, can be eliminated 
2 
when curing barns are retrofitted with heat-exchangers, 
which eliminate the mixing of combustion gases with curing 
air, thereby reducing TSNAs in tobaccos cured in this mauner 
(Boyette & Hamm (2001) Rec. Adv. Tab. Sci. 27:17-22.). In 
5 contrast, in air-cured Burley tobaccos, TSNA formation pri-
marily proceeds through a reaction of tobacco alkaloids with 
nitrite, a process catalyzed by leaf-borne microbes (Bush et 
a!. (2001) Rec. Adv. To b. Sci. 27:23-46). Thus far, attempts to 
reduce TSNAs through modification of curing conditions 
10 while maintaining acceptable quality standards have not been 
successful for air-cured tobaccos. 
In Burley tobacco plants, a positive correlation exists 
between the nornicotine content of a leaf and an amount of 
NNN that accumulates in the cured leaf (Bush eta!. (2001) 
15 Rec. Adv. Tab. Sci, 27:23-46; and Shi eta!. (2000) Tab. Chern. 
Res. Conf 54:Abstract 27). However, keeping nornicotine 
levels at a minimum is difficult in Burley tobacco plants 
because of conversion. Plant breeders and seed producers are 
traditionally responsible for minimizing the number of Bur-
20 ley tobacco plants that accumulate high levels of nornicotine. 
Though the percentage of converters that are ultimately 
grown in fields are reduced through roguing converters during 
propagation of seed stocks. Unfortunately, this process is 
costly, time-consuming and imperfect. 
25 Once a plant converts, the high nornicotine trait is inherited 
as a single dominant gene (Griffith et a!. (1955) Science 
121:343-344; Burke & Jeffrey (1958) Tab. Sci. 2:139-141; 
andManet a!. (1964) Crop Sci. 4:349-353). The nature of this 
gene, however, is currently unknown. In the simplest of sce-
30 narios, the conversion locus may represent a nonfunctional 
nicotine N-demethylase gene that regains its function in con-
verters, possibly through the mobilization of a mutation-in-
ducting transposable element. Alternatively, the converter 
locus may encode a protein that initiates a cascade of events 
35 that ultimately enables converters to metabolize nicotine to 
nornicotine, meaning that multiple genes may be involved. 
Regardless of whether there are one or many genes asso-
ciated with conversion, the gene(s) encoding polypeptides 
having nicotine demethylase activity play a pivotal role in this 
40 process. Although the inability to purify active nicotine 
N -demethylase from crude extracts has impeded the isolation 
and identification of this enzyme, there is some evidence that 
a member of the cytochrome P450 superfamily ofmonooxy-
genases may be involved (Hao & Yeoman (1996) Phytochern. 
45 41:477 -482; Hao & Yeoman (1996) Phytochern. 42:325-329; 
Chelvarajan eta!. (1993) J. Agric, Food Chern. 41:858-862; 
and Hao & Yeoman (1998) J. Plant Physiol. 152:420-426). 
Unfortunately, these studies are not conclusive, as classic 
P450 inhibitors, such as carbon monoxide and tetcylasis, fail 
50 to lower enzyme activity at rates comparable to other reported 
P450-mediated reactions (Chelvarajan eta!. (1993) J. Agric. 
Food Chern. 41:858-862). 
Furthermore, cytochrome P450s are ubiquitous, trans-
membrane proteins that participate in metabolizing a wide 
55 range of compounds (reviewed by Schuler (1996) Crit. Rev. 
Plant Sci. 15:235-284; and Schuler & Werck-Reichhart 
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples ofbio-
chemical reactions mediated by cytochrome P450s include 
hydroxylations, demethylations and epoxidations. In plants, 
60 cytochrome P450 gene families are very large. For example, 
total genome sequence examination revealed 272 predicted 
cytochrome P450 genes in Arabidopsis and at least 455 
unique cytochrome P450 genes in rice (see, e.g., Nelson eta!. 
(2004) Plant Physiol. 135(2):756-772). Even though cyto-
65 chrome P450s have been implicated in the conversion of 
nicotine to nornicotine, identification of key participating 
members of this protein family remains a challenge. 
US 9,228,194 B2 
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Aside from serving as a precursor for NNN, recent studies 
suggest that the nomicotine found in tobacco products has 
undesirable health consequences. For example, Dickerson & 
Janda demonstrated that nomicotine causes aberrant protein 
glycosylation within a cell (Dickerson & Janda (2002) Proc. 
Nat!. A cad. Sci. USA 99: 15084-15088). Likewise, concentra-
tions of nomicotine-modified proteins were much higher in 
plasma of smokers compared to nonsmokers. Furthermore, 
nomicotine can covalently modifY commonly prescribed ste-
roid drugs such as prednisone, which can alter both the effi- 10 
cacy and toxicity of these drugs. 
4 
at 216 is not tyrosine, the residue at 245 is not a tyrosine, and 
the residue at 466 is not valine. 
In a second aspect, the present invention is summarized as 
an expression cassette comprising a polynucleotide encoding 
an amino acid sequence of SEQ ID N0:2 operably linked to 
a promoter that is functional in a plant cell. The present 
invention provides an expression cassette comprises a poly-
nucleotide comprising a nucleic acid sequence of SEQ ID 
N0:3, or a fragment of at least 25 contiguous nucleic acids 
thereof, operably linked to a promoter that is functional in a 
plant cell. Also provided is an isolated polynucleotide com-
prising at least 25 nucleotides of a nucleic acid sequence of 
SEQ ID N0:3. Further provided is an isolated polypeptide 
comprising an amino acid sequence selected from the group 
In view of the difficulties associated with conversion, as 
well as the undesirable health effects of nomicotine accumu-
lation, improved methods for reducing the nomicotine con-
tent in tobacco varieties, particularly Burley tobacco plants, 
are therefore desirable. Such methods would not only help 
ameliorate the potential negative health consequences of the 
nomicotine per seas described above, but also help to reduce 
NNNlevels. 
15 consisting of SEQ ID N0:2, 5-12 and 14-24. In one embodi-
ment of the second aspect, the isolated polypeptide comprises 
an amino acid sequence 99% identical to SEQ ID N0:2, such 
that it is capable of converting nicotine to nomicotine in green 
leaves of tobacco. 
20 
SUMMARY OF THE INVENTION 
In a third aspect, the present invention is summarized as a 
plant of the genus Nicotiana or a plant part thereof comprising 
an expression cassette, the cassette encoding SEQ ID N0:2, a 
fragment thereof, or a complement of either. Also provided is 
a transgenic Nicotiana plant having a lower level of nicotine 
Compositions and methods are provided for reducing the 
nomicotine content in plants that are members of the genus 
Nicotiana. Compositions include isolated cytochrome P450 
polynucleotides and polypeptides that are involved in conver-
sion of nicotine to nomicotine in plants, particularly Nicoti-
ana species. Isolated polynucleotides include those that com-
prise a nucleic acid sequence as set forth in SEQ ID NO: 1, 3 
25 to nomicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a first nucleic acid sequence comprising a region of 
30 between about 100 nucleic acids and about 350 nucleic acids or 4, a nucleic acid sequence encoding a polypeptide as set 
forth in SEQ ID N0:2, 5-12, 14-24, and fragments and vari-
ants thereof. Isolated polypeptides of the invention include 
those that comprise an amino acid sequence as set forth in 
SEQ ID N0:2, 5-12 or 14-24, an amino acid sequence 
encoded by the nucleic acid sequence set forth in SEQ ID 35 
NO: 1, 3 or 4, and fragments and variants thereof. 
In a first aspect, the present invention is summarized as 
polynucleotides that can suppress expression of a nicotine 
demethylase involved in the metabolic conversion of nicotine 
to nornicotine in a plant, including the nicotine demethylases 40 
of the present invention. The present invention provides an 
isolated polynucleotide having a promoter capable of func-
tioning in a plant cell operably linked to a nucleic acid 
sequence comprising a region of between about 100 nucleic 
acids and about 350 nucleic acids of SEQ ID NO: 1 obtained 45 
from a sequence selected from the group of nucleic acids at 
position 253, 353, 647, 733, 1050, 1397 and combinations 
thereof. The present invention also provides an isolated poly-
nucleotide comprising a nucleic acid sequence encoding a 
green-leaf nicotine demethylase, where the amino acid 50 
sequence of the encoded nicotine demethylase has a substi-
tution at an amino acid residue in a position selected from the 
group consisting of residues 235,449, 174,410,224,72, 143 
and 422, where the numbering is according to SEQ ID N0:2. 
Also provided is an isolated polynucleotide comprising a 55 
promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence comprising a region of 
between about 100 nucleic acids and about 350 nucleic acids 
of SEQ ID N0:4. Further provided is an isolated polynucle-
otide encoding an amino acid sequence as set forth in SEQ ID 60 
N0:2 with a mutation of a residue that differs from the other 
of a green-leaf tobacco nicotine demethylase sequence 
encoding an amino acid sequence of SEQ ID N0:2 and a 
second nucleic acid sequence capable of forming a double 
stranded RNA with the first sequence. Further provided is a 
transgenic Nicotiana plant having a lower level of nicotine to 
nornicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a first nucleic acid sequence comprising a region of 
between about 100 nucleic acids and about 350 nucleic acids 
of a green-leaf tobacco nicotine demethylase sequence hav-
ing the nucleic acid sequence of SEQ ID N0:3 and a second 
nucleic acid sequence capable of forming a double stranded 
RNA with the first sequence is provided. Also provided is a 
transgenic Nicotiana plant having a lower level of nicotine to 
nornicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a first nucleic acid sequence comprising a region of 
between about 100 nucleic acids and about 350 nucleic acids 
of a green-leaf tobacco nicotine demethylase sequence hav-
ing a nucleic acid sequence of SEQ ID N0:4 and a second 
nucleic acid sequence capable of forming a double stranded 
RNA with the first sequence. 
In a fourth aspect, the present invention is summarized as a 
seed of a transgenic Nicotiana plant having a lower level of 
nicotine to nomicotine conversion rate in green leaves com-
pared to a non-transgenic plant, the plant comprising a heter-
ologous promoter capable of functioning in a plant cell oper-
ably linked to a polynucleotide having a first nucleic acid 
sequence comprising a region of between about 100 nucleic 
acids and about 350 nucleic acids of a green-leaf tobacco 
P450 polypeptides to a conserved residue. Alternatively pro-
vided is an isolated polynucleotide encoding an amino acid 
sequence as set forth in SEQ ID N0:2 with a mutation at a 
position selected from the group consisting of residues 85, 
118, 216, 245 and 466, where the residue at 85 is not an 
isoleucine, the residue at 118 is not an asparagine, the residue 
65 nicotine demethylase sequence having an amino acid 
sequence of SEQ ID N0:4 and a second nucleic acid 
sequence capable of forming a double stranded RNA with the 
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first sequence. Also provided is a tissue culture of regenerable 
tobacco cells comprising a plant cell that comprises a first 
polynucleotide having a fragment of the nucleic acid 
sequence of SEQ ID NO: 1, 3 or 4 and a second polynucle-
otide capable of forming a double stranded RNA with the 
first. 
In a fifth aspect, the present invention is summarized as a 
tobacco product comprising a transgenic Nicotiana plant cell 
having a lower level of nicotine to nornicotine conversion rate 
in green leaves compared to a non-transgenic plant, the plant 
cell comprising a heterologous promoter capable of function-
ing in a plant cell operably linked to a polynucleotide having 
a first nucleic acid sequence comprising a region of between 
about 100 nucleic acids and about 350 nucleic acids of a 
green-leaf tobacco nicotine demethylase sequence having a 
nucleic acid sequence of SEQ ID N0:4 and a second poly-
nucleotide capable of forming a double stranded RNA with 
the first. Also provided is a tobacco cell having a genome 
altered to inhibit the expression of at least a green-leaf nico-
tine demethylase, where the cell is homozygous for a muta-
tion in the gene encoding the green-leaf nicotine demethy-
lase. Further provided is a tobacco cell comprising a 
trans gene containing green-leaf nicotine demethylase nucleic 
acid sequence that flanks a selectable marker gene, where the 
selectable marker gene disrupts the nicotine demethylase 
gene, thereby producing a tobacco cell where the endogenous 
green-leaf nicotine demethylase gene has been disrupted. 
Alternatively provided is a tobacco cell comprising a trans-
gene containing green-leaf nicotine demethylase nucleic acid 
sequence that flanks a selectable marker gene, where the 
selectable marker gene disrupts the nicotine demethylase 
gene, thereby producing a tobacco cell where the endogenous 
green-leaf nicotine demethylase gene has been disrupted. 
In a sixth aspect, the present invention is summarized as a 
method for reducing nornicotine levels in a plant part derived 
from a plant of the genus Nicotiana, the method comprising a) 
inhibiting expression of a nicotine demethylase, where the 
nicotine demethylase has an amino acid sequence set forth in 
the group consisting of SEQ ID NOs: 2 and 5-12; and b) 
reducing nornicotine levels in a plant part derived from a plant 
of the genus Nicotiana. Also provided is a method for reduc-
ing nornicotine levels in a tobacco product, the method com-
prising a) growing a transgenic tobacco plant, where the plant 
having a plant part that comprises an expression cassette 
comprising a heterologous promoter and a nicotine demethy-
lase, where the nicotine demethylase has an amino acid 
sequence selected from the group consisting of SEQ ID 
NOs:2 and 5-12; and b) preparing a tobacco product from the 
tobacco plant part. Further provided is a method for reducing 
nornicotine levels in a tobacco product, the method compris-
ing a) growing a transgenic tobacco plant, where the plant has 
a plant part that comprises an antibody that specifically binds 
a polypeptide with an amino acid sequence selected from the 
group consisting of SEQ ID NOs:2 and 5-12; and b) preparing 
6 
functional CYP82E5v2, where the nonfunctional 
CYP82E5v2 has a substitution at an amino acid residue in a 
position selected from the group consisting of residues 235, 
449, 17 4, 410, 224, 72, 143 and 422, where the numbering is 
according to SEQ ID N0:2; and b) reducing the level of 
nornicotine in a plant part derived from a plant of the genus 
Nicotiana. The present invention also provides a method for 
reducing the carcinogenic potential of a tobacco product, the 
method comprising preparing the tobacco product by a) 
10 growing a transgenic tobacco plant, where the plant com-
prises a plant part that comprises a fragment of a green-leaf 
nicotine demethylase operably linked to a heterologous pro-
moter and the fragment comprises at least 25 contiguous 
nucleic acids from a polynucleotide encoding a polypeptide 
15 selected from the group consisting of SEQ ID NOs:2 and 
5-12; and b) preparing a tobacco product from the tobacco 
plant part. Further, the present invention provides a method of 
reducing the conversion of nicotine to nornicotine in a Nic-
otiana plant comprising: a) transforming a Nicotiana plant 
20 with an nucleic acid construct comprising a promoter capable 
offunctioning in a plant cell operably linked to a polynucle-
otide having a first nucleic acid sequence comprising a region 
of between 100 nucleic acids and about 350 nucleic acids of 
SEQ ID NO: 1, 3 or 4 and a second nucleic acid sequence 
25 capable of forming a double stranded RNA with the first 
sequence; and b) regenerating a transgenic Nicotiana plant. 
In a seventh aspect, the present invention is summarized as 
a method of screening for a green-leaf nicotine demethy lase 
sequence comprising a) obtaining a nucleic acid sequence 
30 that has at least 200 nucleic acids of sequence identity with 
SEQ ID NO: 1; and b) identifYing a codon sequence encoding 
for a stop codon at position 422 of an encoded polypeptide, 
where the numbering is according to SEQ ID N0:2. Also 
provided is a method of screening for green-leaf nicotine 
35 demethylase sequence comprising a) obtaining a nucleic acid 
sequence that has at least 200 nucleic acids of sequence 
identity with SEQ ID NO: 1; and b) identifying a codon 
sequence encoding for a codon that is not a proline at position 
449 of an encoded polypeptide, where the numbering is 
40 according to SEQ ID N0:2. Further provided is a method for 
identifying a tobacco plant with low levels of nornicotine, the 
method comprising a) obtaining a DNA sample from a 
tobacco plant of interest; and b) screening the sample for a 
mutation in SEQ ID NO: 1. The present invention also pro-
45 vides a method for reducing the level of nornicotine in a plant 
part derived from a plant of the genus Nicotiana, the method 
comprising a) inhibiting expression of a CYP82E4v2 nico-
tine demethylase and CYP82E5v2 nicotine demethylase; and 
b) reducing the level of nornicotine in a plant part derived 
50 from a plant of the genus Nicotiana. Also included is tobacco 
plant material comprising a polypeptide with an amino acid 
sequence of SEQ ID NO: 13 having a mutation at a position 
selected from the group consisting of residues 458, 364, 329 
and combinations thereof. Further included is tobacco plant 
55 material comprising a CYP82E4v2 having a mutation at a 
position selected from the group consisting of residues 458, 
364, 329 and combinations thereof, where the numbering 
corresponds to SEQ ID NO: 13. Also included is tobacco plant 
material comprising a CYP82E4 v2 having a mutation at resi-
a tobacco product from the tobacco plant part. Alternatively 
provided is a method for reducing nornicotine levels in a 
tobacco product, the method comprising a) growing a trans-
genic tobacco plant, where the plant has a plant part that 
comprises a fragment of a green-leaf nicotine demethylase 
operably linked to a heterologous promoter and the fragment 
has at least 25 contiguous nucleic acids from a polynucleotide 
encoding a polypeptide selected from the group consisting of 
SEQ ID NOs:2 and 5-12; and b) preparing a tobacco product 
from the tobacco plant part. Also provided is a method for 
reducing nornicotine levels in a plant part derived from a plant 65 
of the genus Nicotiana, the method comprising a) modifying 
the functional CYP82E5v2 allele to change alleles to a non-
60 due 376, where the residue is not valine and the numbering of 
residues corresponds to SEQ ID NO: 13. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. lA-C show an amino acid sequence aligrnnent of 
CYP82E2 gene family members that have been assayed for 
nicotine demethylase activity in yeast and/or transgenic 
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plants. Sequences in italics and underlined are positive for 
nicotine demethylase activity (CYP82E4v2 and 
CYP82E5v2); sequences titled in black failed to show activ-
ity in an assay. Residues that differ among the members are 
shaded in grey. In FIG. 1, CYP82E4v2 is set forth in SEQ ID 5 
N0:13; CYP82E4v6 is set forth in SEQ ID N0:26; 
CYP82E4v12 is set forth in SEQ ID N0:27; 58-166 is set 
forth in SEQ ID N0:28; CYP82E3 is set forth in SEQ ID 
8 
SEQ ID N0:27 sets forth an amino acid sequence of a 
CYP82E4v12. 
SEQ ID N0:28 sets forth an amino acid sequence of a 
58-166. 
SEQ ID N0:29 sets forth an amino acid sequence of a 
CYP82E3. 
SEQ ID N0:30 sets forth an amino acid sequence of a 
CYP82E2v1. 
N0:29; CYP82E2v1 is set forth in SEQ ID N0:30; SEQ ID N0:31 sets forth an amino acid sequence of a 
CYP82E2v2 is set forth in SEQ ID N0:31; and CYP82E5v2 10 CYP82E2v2. 
is set forth in SEQ ID N0:2. SEQ ID N0:32 sets forth a nucleic acid sequence of a 
DESCRIPTION OF THE NUCLEIC ACID 
SEQUENCES 
SEQ ID NO: 1 sets forth a nucleic acid sequence of a coding 
region ofCYP82E5v2. 
SEQ ID N0:2 sets forth an amino acid sequence of a 
CYP82E5v2. 
15 
forward primer for exon 1 of CYP82E4v2. 
SEQ ID N0:33 sets forth a nucleic acid sequence of a 
reverse primer for exon 1 ofCYP82E4v2. 
SEQ ID N0:34 sets forth a nucleic acid sequence of a 
forward primer for exon 2 of CYP82E4v2. 
SEQ ID N0:35 sets forth a nucleic acid sequence of a 
reverse primer for exon 2 ofCYP82E4v2. 
SEQ ID N0:3 sets forth a nucleic acid sequence of an 20 
intron ofCYP82E5v2. 
SEQ ID N0:36 sets forth a nucleic acid sequence of a 
forward primer for exon 1 of CYP82E5v2. 
SEQ ID N0:37 sets forth a nucleic acid sequence of a 
reverse primer for exon 1 of CYP82E5v2. SEQ ID N0:4 sets forth a nucleic acid sequence of a 
genomic CYP82E5v2. 
SEQ ID N0:5 sets forth an amino acid sequence of a 
CYP82E5v2 P235S. 
SEQ ID N0:6 sets forth an amino acid sequence of a 
CYP82E5v2 P449L. 
SEQ ID N0:7 sets forth an amino acid sequence of a 
CYP82E5v2 S174L. 
25 
SEQ ID N0:38 sets forth a nucleic acid sequence of a 
forward primer for exon 2 of CYP82E5v2. 
SEQ ID N0:39 sets forth a nucleic acid sequence of a 
reverse primer for exon 2 of CYP82E5v2. 
SEQ ID N0:40 sets forth a nucleic acid sequence of a 
primer E5Gen_F1. 
SEQ ID N0:8 sets forth an amino acid sequence of a 30 
CYP82E5v2 A41 OV. 
SEQ ID N0:41 sets forth a nucleic acid sequence of a 
primer E5Gen_R1. 
SEQ ID N0:42 sets forth a nucleic acid sequence of a 
primer E5Gen_F2. SEQ ID N0:9 sets forth an amino acid sequence of a 
CYP82E5v2 M224I. 
SEQ ID NO: 10 sets forth an amino acid sequence of a 
CYP82E5v2 P72L. 
SEQ ID NO: 11 sets forth an amino acid sequence of a 
CYP82E5v2 L143F. 
SEQ ID N0:12 sets forth an amino acid sequence of a 
CYP82E5v2 W422Stop. 
SEQ ID N0:13 sets forth an amino acid sequence of a 
CYP82E4v2. 
SEQ ID N0:14 sets forth an amino acid sequence of a 
CYP82E4v2 P458S. 
SEQ ID NO: 15 sets forth an amino acid sequence of a 
CYP82E4v2 K364N. 
SEQ ID NO: 16 sets forth an amino acid sequence of a 
CYP82E4v2 P38L. 
SEQ ID NO: 17 sets forth an amino acid sequence of a 
CYP82E4v2 E201K. 
35 
SEQ ID N0:43 sets forth a nucleic acid sequence of a 
primer E5Gen_R2. 
SEQ ID N0:44 sets forth a nucleic acid sequence of a 
primer E4Rt_F. 
SEQ ID N0:45 sets forth a nucleic acid sequence of a 
primer E4Rt_R. 
SEQ ID N0:46 sets forth a nucleic acid sequence of a 
40 primer E5Rt_F. 
45 
SEQ ID N0:47 sets forth a nucleic acid sequence of a 
primer E5Rt_R. 
SEQ ID N0:48 sets forth a nucleic acid sequence of a 
primer G3PDH_F. 
SEQ ID N0:49 sets forth a nucleic acid sequence of a 
primer G3PDH_R. 
SEQ ID N0:50 sets forth a nucleic acid sequence of a 
coding region of CYP82E4v2 and the encoded protein (i.e., 
SEQ ID N0:13). 
SEQ ID NO: 18 sets forth an amino acid sequence of a 50 
CYP82E4v2 R169Q. DEFINITIONS 
SEQ ID NO: 19 sets forth an amino acid sequence of a 
CYP82E4v2 G459R. 
SEQ ID N0:20 sets forth an amino acid sequence of a 
CYP82E4v2 E296K. 
SEQ ID N0:21 sets forth an amino acid sequence of a 
CYP82E4v2 T427I. 
SEQ ID N0:22 sets forth an amino acid sequence of a 
CYP82E4v2 W329Stop. 
The present invention includes compositions and methods 
for inhibiting expression or function of nicotine demethylase 
55 polypeptides that are involved in the metabolic conversion of 
nicotine to nornicotine in a plant, particularly plants of the 
Nicotiana genus, including tobacco plants of various com-
mercial varieties. 
SEQ ID N0:23 sets forth an amino acid sequence of a 60 
CYP82E4v2 V376M. 
As used herein, "inhibit," "inhibition" and "inhibiting" are 
defined as any method known in the art or described herein, 
which decreases the expression or function of a gene product 
of interest (i.e., the target gene product). SEQ ID N0:24 sets forth an amino acid sequence of a 
CYP82E4v2 D171N. 
SEQ ID N0:25 sets forth an amino acid sequence of a 
CYP82E4. 
SEQ ID N0:26 sets forth an amino acid sequence of a 
CYP82E4v6. 
"Inhibiting" can be in the context of a comparison between 
two plants, for example, a genetically altered plant versus a 
65 wild-type plant. The comparison can be between plants, one 
of which lacks a DNA sequence capable of reducing the 
agent. Inhibition of expression or function of a target gene 
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product also can be in the context of a comparison between 
plant cells, organelles, organs, tissues or plant parts within the 
same plant or between different plants, and includes com pari-
sons between developmental or temporal stages within the 
same plant or plant part or between plants or plant parts. 
"Inhibiting" can include any relative decrement of function 
or production of a gene product of interest, up to and includ-
ing complete elimination of function or production of that 
gene product. When levels of an agent are compared, such a 
comparison is preferably carried out between organisms with 
a similar genetic background. Preferably, a similar genetic 
background is a background where the organisms being com-
pared share 50% or greater, more preferably 75% or greater, 
and, even more preferably 90% or greater sequence identity 
10 
pos1t!on. See, FIGS. lA-C. As used herein, a "fragment" 
means a portion of a polynucleotide or a portion of a polypep-
tide and hence protein encoded thereby. 
As used herein, "plant part" means plant cells, plant pro-
toplasts, plant cell tissue cultures from which a whole plant 
can be regenerated, plant calli, plant clumps and plant cells 
that are intact in plants or parts of plants such as embryos, 
pollen, anthers, ovules, seeds, leaves, flowers, stems, 
branches, fruit, roots, root tips and the like. Progeny, variants 
10 and mutants of regenerated plants are also included within the 
scope of the present invention, provided that they comprise 
the introduced polynucleotides of the invention. As used 
herein, "tobacco plant material" means any portion of a plant 
part or any combination of plant parts. 
of nuclear genetic material. A similar genetic background is a 15 
background where the organisms being compared are plants, 
and the plants are isogenic except for any genetic material 
originally introduced using plant transformation techniques 
As used herein, "operably linked" means a functional link-
age between two or more elements. For example, an operable 
linkage between a polynucleotide of interest and a regulatory 
sequence (i.e., a promoter) is a functional link that allows for 
expression of the polynucleotide of interest. Operably linked or a mutation generated by human intervention. Measurement 
of the level or amount of an agent may be carried out by any 
suitable method, non-limiting examples of which include, but 
are not limited to, comparison of mRNA transcript levels, 
protein or peptide levels, and/or phenotype, especially the 
conversion of nicotine to nornicotine. As used herein, mRNA 
transcripts can include processed and non-processed mRNA 
transcripts, and polypeptides or peptides can include 
polypeptides or peptides with or without any post-transla-
tional modification. 
As used herein, "host cell" means a cell that comprises a 
heterologous nucleic acid sequence of the invention. Though 
the nucleic acid sequences of the invention, and fragments 
and variants thereof, can be introduced into any cell of inter-
est, of particular interest are plant cells, more particularly 
cells of a Nicotiana plant species, for example, the tobacco 
plant species and varieties described herein below. 
As used herein, "variant" means a substantially similar 
sequence. A variant can have different function or a substan-
tially similar function as a wild-type polypeptide of interest. 
For a nicotine demethylase, a substantially similar function is 
20 elements may be contiguous or non-contiguous. When used 
to refer to the fusing of two protein coding regions, by oper-
ably linked is intended that the coding regions are in the same 
reading frame. 
As used herein, "heterologous" means a sequence that 
25 originates from a foreign species, or, if from the same species, 
is substantially modified from its native form in composition 
and/or genomic locus by deliberate human intervention. For 
example, a promoter operably linked to a heterologous poly-
nucleotide is from a species different from the species from 
30 which the polynucleotide was derived, or, if from the same/ 
analogous species, one or both are substantially modified 
from their original form and/or genomic locus, or the pro-
moter is not the native promoter for the operably linked poly-
nucleotide. Furthermore, as used herein, "chimeric gene" 
35 means a coding sequence operably linked to a transcription 
initiation region that is heterologous to the coding sequence. 
DETAILED DESCRIPTION OF THE INVENTION 
at least 99%, 98%, 97%, 95%, 90%, 85%, 80%,75%, 60%, 40 
50%, 25% or 15% of wild-type enzyme function of convert-
ing nicotine to nomicotine under the same conditions or in a 
near-isogenic line.A wild-type CYP82E5v2 is SEQ ID N0:2. 
Nicotine Demethylase Polynucleotides and Polypeptides, 
and Variants and Fragments Thereof 
Compositions of the present invention include cytochrome 
P450 polypeptides. Cytochrome P450 polypeptides can have 
nicotine demethylase activity. Such nicotine demethylase 
polynucleotides and polypeptides are involved in the meta-
bolic conversion of nicotine to nomicotine in plants, includ-
A wild-type CYP82E4v2 is SEQ ID N0:13. As used herein, 
a "variant polynucleotide" or "variant polypeptide" means a 45 
nucleic acid or amino acid sequence that is not wild-type. 
ing commercial varieties of tobacco plants. Also included are 
variants of such nicotine demethylases. In particular, compo-
sitions of the invention include isolated polypeptides com-
prising amino acid sequences as shown in SEQ ID NOS:2 and 
5-24, isolated polynucleotides comprising the nucleic acid 
sequences as shown in SEQ ID NOS:1, 3 and 4, and the 
isolated polynucleotides encoding polypeptides comprising 
amino acid sequences of SEQ ID NOS:2 and 5-24. The poly-
A variant can have one addition, deletion or substitution; 
two or less additions, deletions or substitutions; three or less 
additions, deletions or substitutions; four or less additions, 
deletions or substitutions; or five or less additions, deletions 50 
or substitutions. A mutation includes additions, deletions, and 
substitutions. Such deletions or additions can be at the C-ter-
minus, N-terminus or both the C- and N-termini. Fusion 
polypeptides or epitope-tagged polypeptides are also 
included in the present invention. "Silent" nucleotide muta-
tions do not change the encoded amino acid at a given posi-
tion. Amino acid substitutions can be conservative. A conser-
vative substitution is a change in the amino acid where the 
change is to an amino acid within the same family of amino 
acids as the original amino acid. The family is defined by the 
side chain of the individual amino acids. A family of amino 
acids can have basic, acidic, uncharged polar or nonpolar side 
chains. See, Alberts eta!., (1994) Molecular biology of the 
cell (3rd ed., pages 56-57, Garland Publishing Inc., New 
York, N.Y.), incorporated herein by reference as if set forth in 
55 nucleotides of the present invention can find use in inhibiting 
expression of nicotine demethylase polypeptides or variants 
thereof that are involved in the metabolic conversion of nico-
tine to nomicotine in plants, particularly tobacco plants. 
Some of the polynucleotides of the invention have mutations 
its entirety. A deletion, substitution or addition can be to the 
amino acid of another CYP82E family member in that same 
60 that inhibit nicotine demethylase activity of the wild-type 
nicotine demethylase. The inhibition of polypeptides of the 
present invention is effective in lowering nomicotine levels in 
tobacco lines where genetic conversion occurs in less than 
30%, 50%, 70% and 90% of the population, such as flue-
65 cured tobaccos. The inhibition of polypeptides of the present 
invention is effective in lowering nomicotine levels in 
tobacco populations where genetic conversion occurs in at 
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least 90%, 80%, 70%, 60% and 50% of a plant population. A 
population preferably contains greater than about 25, 50, 100, 
500, 1,000, 5,000 or 25,000 plants where, more preferably at 
least about 10%,25%,50%,75%, 95% or 100% of the plants 
comprise a polypeptide of the present invention. 
The present invention further provides expression cassettes 
comprising all or a portion of the polynucleotides having a 
nucleic acid sequence set forth in SEQ ID NO: 1, 3 or 4, and 
the isolated polynucleotides encoding polypeptides having an 
amino acid sequence of SEQ ID NOS: 2 and 5-24, a comple- 10 
ment or fragment thereof, or a sequence having substantial 
sequence identity to SEQ ID NO: 1, 3 or 4, or the polynucle-
otides encoding polypeptides having an amino acid sequence 
of SEQ ID NOS:2 and 5-24, or a complement or fragment 
thereof, operably linked to a heterologous promoter that is 15 
functional in a plant cell for use in expressing an inhibitory 
RNA transcript that interferes with expression (i.e., transcrip-
tion and/or translation) of nicotine demethylase polypeptides. 
In some embodiments, the expression cassettes comprise the 
nucleotide sequence as shown in SEQ ID N0:1, 3 or 4, a 20 
complement or fragment thereof, or a sequence having sub-
stantial sequence identity to SEQ ID NO: 1, 3 or 4, or a 
complement or fragment thereof. Introduction of these 
expression cassettes into a Nicotiana plant of interest; par-
ticularly a tobacco plant of varieties commonly known as flue 25 
or bright varieties, Burley varieties, dark varieties and orien-
tal/Turkish varieties, results in the production of tobacco 
plants having reduced amounts of nornicotine and NNN. Leaf 
and stem material from these transgenic plants can be used to 
produce a variety of tobacco products having, reduced levels 30 
of nornicotine, and a concomitant reduction NNN. 
The nicotine demethylase polynucleotides and encoded 
polypeptides of the present invention include a novel cyto-
chrome P450 gene, designated the CYP82E5v2 nicotine 
demethylase gene, that is newly identified as having a role in 35 
the metabolic conversion of nicotine to nornicotine in tobacco 
plants. Suppressionofthe expression of the encoded polypep-
tide in transgenic tobacco plants results in a significant reduc-
tion in the accumulation of nornicotine in the green leaves of 
these transgenic plants. While not being bound by theory, the 40 
metabolic role of these polypeptides may be a direct one, i.e., 
directly catalyzing the N-demethylation reaction, or an indi-
rect one, i.e., in the form of production of a product that leads 
12 
otide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 
0.5 kb or0.1 kb of nucleotide sequence that naturally flank the 
polynucleotide in genomic DNA of the cell from which the 
polynucleotide is derived. A polypeptide that is substantially 
free of cellular material includes preparations having less 
than about 30%, 20%, 10%, 5% or 1% (by dry weight) of 
contaminating protein. When the polypeptide of the invention 
or biologically active portion thereof is recombinantly pro-
duced, optimally culture medinm represents less than about 
30% 20%, 10%, 5% or 1% (by dry weight) of chemical 
precursors or non-protein-of-interest chemicals. 
Fragments of the disclosed polynucleotides and polypep-
tides encoded thereby are also encompassed by the present 
invention. Fragments of a polynucleotide may encode 
polypeptide fragments that retain the biological activity of the 
native polypeptide and hence are involved in the metabolic 
conversion of nicotine to nornicotine in a plant. Alternatively, 
fragments of a polynucleotide that are useful as hybridization 
probes or PCR primers using methods described below gen-
erally do not encode fragment polypeptides retaining biologi-
cal activity. Furthermore, fragments of the disclosed poly-
nucleotides include those that can be assembled within 
recombinant constructs for use in gene silencing with any 
method known in the art, including, but not limited to, sense 
suppression/cosuppression, antisense suppression, double-
stranded RNA (dsRNA) interference, hairpin RNA interfer-
ence and intron-containing hairpin RNA interference, ampli-
con-mediated interference, ribozymes and small interfering 
RNA or micro RNA, as described in the art and herein below. 
Thus, fragments of a polynucleotide may range from at least 
about 20 nucleotides, about 50 nucleotides, about 70 nucle-
otides, about 100 nucleotides about 150 nucleotides, about 
200 nucleotides, 250 nucleotides, 300 nucleotides and up to 
the full-length polynucleotide encoding the polypeptides of 
the invention, depending upon the desired outcome. For 
example, the fragments of a polynucleotide can be between 
100 and about 350 nucleotides, between 100 and about 325 
nucleotides, between 100 and about 300 nucleotides, between 
about 125 and about 300 nucleotides, between about 125 and 
about 275 nucleotides in length, between about 200 to about 
320 contiguous nucleotides, between about 200 and about 
420 contiguous nucleotides in length between about 250 and 
about 450 contiguous nucleotides in length. Alternatively, the 
fragment can be between about 300 and about 450 contiguous 
nucleotides in length. 
A fragment of a nicotine demethylase polynucleotide of 
the present invention that encodes a biologically active por-
tion of a cytochrome P450 polypeptide of the present inven-
tion will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 
to the up-regulation of the nicotine demethylase activity of 
the leaf. Regardless of the mechanism, any means by which 45 
expression and/or function of the polypeptides of the present 
invention are targeted for inhibition or site-directed mutagen-
esis within a Nicotiana plant will be effective in reducing 
nornicotine levels, and levels of NNN, within leaves and 
stems of these plants. 50 200, 250, 300, 350, 400, 450 or 500 contiguous amino acids, 
or up to the total number of amino acids present in a full-
length nicotine demethylase polypeptide of the invention 
(e.g., 517 amino acids for SEQ ID NOS:2 and 5), or will 
The invention encompasses isolated or substantially puri-
fied polynucleotide or polypeptide compositions of the 
present invention. An "isolated" or "purified" polynucleotide 
or polypeptide, or biologically active portion thereof, is sub-
stantially or essentially free from components that normally 55 
accompany or interact with the polynucleotide or protein as 
found in its naturally occurring environment. Thus, an iso-
lated or purified polynucleotide or polypeptide is substan-
tially free of other cellular material or culture medium when 
produced by recombinant techniques, or substantially free of 60 
chemical precursors or other chemicals when chemically syn-
thesized. Optimally, an "isolated" polynucleotide is free of 
sequences (optimally protein encoding sequences) that natu-
rally flank the polynucleotide (i.e., sequences located at the 5' 
and 3' ends of the polynucleotide) in the genomic DNA of the 65 
organism from which the polynucleotide is derived. For 
example, in various embodiments, the isolated polynucle-
encode at least 15, 25, 30, 50, 75, 100, 125, 150 or up to the 
total nnmber of amino acids present in a partial-length cyto-
chrome P450 polypeptide of the invention (e.g., 422 for SEQ 
ID N0:12). Preferably, the fragment comprises up to amino 
acid residue 330 of the encoded polypeptide. A biologically 
active portion of a nicotine demethylase polypeptide can be 
prepared by isolating a portion of one of the cytochrome P450 
polynucleotides of the present invention, expressing the 
encoded portionofthe cytochrome P450 polypeptide (e.g., by 
recombinant expression in vitro), and assessing the activity of 
the encoded portion of the cytochrome P450 polypeptide, i.e., 
the ability to promote conversion of nicotine to nornicotine, 
using assays known in the art and those provided herein 
below. 
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Polynucleotides that are fragments of a cytochrome P450 
nucleotide sequence of the present invention comprise at least 
16,20, 50, 75,100,150,200,250,300,350,400,450,500, 
550, 600, 650,700,800, 900, 950, 1000, 1050, 1100, 1150, 
1200,1250,1300,1350,1400,1450,1500,1550,1600,1650 
or 1700 contiguous nucleic acids, or up to the number of 
nucleotides present in a full-length cytochrome P450 poly-
nucleotide as disclosed herein (e.g., 1554 for SEQ ID NO: 1; 
or 2608 for SEQ ID N0:4). Polynucleotides that are frag-
ments of a cytochrome P450 nucleotide sequence of the 
present invention comprise fragments from about 20 to about 
1700 contiguous nucleic acids, from about 50 to about 1600 
contiguous nucleic acids, from about 75 to about 1500 con-
tiguous nucleic acids, from about 100 to about 1400 nucleic 
acids, from about 150 to about 1300 contiguous nucleic acids, 
from about 150 to about 1200 contiguous nucleic acids, from 
about 17 5 to about 1100 contiguous nucleic acids, from about 
200 to about 1000 contiguous nucleic acids, from about 225 
to about 900 contiguous nucleic acids, from about 500 to 
about 1600 contiguous nucleic acids, from about 77 5 to about 
1700 contiguous nucleic acids, from about 1000 to about 
1700 contiguous nucleic acids, or from about 300 to about 
800 contiguous nucleic acids from a cytochrome P450 poly-
nucleotide as disclosed herein. For example, polynucleotide 
fragment can comprise a polynucleotide sequence containing 
the nucleic acid sequence from the polynucleotide at about 
position 700 to about position 1250 of a cytochrome P450 
coding sequence, at about position 700 to about position 1250 
of a cytochrome P450 genomic sequence, at about position 10 
to about position 900 of a cytochrome P450 intron sequence, 
or at about position 100 to about position 800 of a cytochrome 
P450 intron sequence. 
Variants of the disclosed polynucleotides and polypeptides 
encoded thereby are also encompassed by the present inven-
tion. Naturally occurring variants include those variants that 
share substantial sequence identity to the disclosed cyto-
chrome P450 polynucleotides and polypeptides disclosed 
herein. Naturally occurring variants can share substantial 
functional identity to the disclosed cytochrome P450 poly-
nucleotides disclosed herein. The compositions and methods 
of the invention can be used to target expression or function of 
any naturally occurring cytochrome P450 that shares substan-
tial sequence identity to the disclosed cytochrome P450 
polypeptides. Such cytochrome P450 can possess the relevant 
cytochrome P450 activity, i.e., involvement in the metabolic 
conversion of nicotine to nornicotine in plants, or not. Such 
variants may result from, e.g., genetic polymorphism or from 
human manipulation as occurs with breeding and selection. 
Biologically active variants of a cytochrome P450 protein of 
the invention, such as variants of the polypeptide set forth in 
SEQ ID N0:2 and 5-24, will have at least about 40%, 45%, 
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
sequence identity to the amino acid sequence for the wild-
type protein as determined by sequence alignment programs 
and parameters described elsewhere herein, and can be char-
acterized by a functional involvement in the metabolic con-
version of nicotine to nomicotine in plants or lack thereof. A 
biologically active variant of a polypeptide of the invention 
may differ by as few as 1-15 amino acid residues, as few as 10, 
as few as 9, as few as 8, as few as 7, as few as 6, as few as 5, 
as few as 4, as few as 3, as few as 2, or as few as 1 amino acid 
residue from the wild-type polypeptide. A biologically inac-
tive variant of a protein of the invention may differ from that 
polypeptide by as few as 1-15 amino acid residues, as few as 
14 
10, as few as 9, as few as 8, as few as 7, as few as 6, as few as 
5, as few as 4, as few as 3, as few as 2, or as few as 1 amino acid 
residue. 
Variants of the polynucleotides of the present invention 
include those naturally occurring polynucleotides that encode 
a nicotine demethylase polypeptide that is involved in the 
metabolic conversion of nicotine to nornicotine in plants. 
Such polynucleotide variants can comprise a deletion and/or 
addition of one or more nucleotides at one or more sites 
10 within the native polynucleotide disclosed herein and/or a 
substitution of one or more nucleotides at one or more sites in 
the native polynucleotide. Because of the degeneracy of the 
genetic code, conservative variants for polynucleotides 
15 
include those sequences that encode the amino acid sequence 
of one of the cytochrome P450 polypeptides of the invention. 
Naturally occurring variants such as these can be identified 
with the use of well-known molecular biology techniques, as, 
e.g., with polymerase chain reaction (PCR) and hybridization 
20 techniques as are known in the art and disclosed herein. 
Variant polynucleotides also include synthetically derived 
polynucleotides, such as those generated, e.g., by using site-
directed mutagenesis but which still share substantial 
sequence identity to the naturally occurring sequences dis-
25 closed herein, and thus can be used in the methods of the 
invention to inhibit the expression or function of a nicotine 
demethylase that is involved in the metabolic conversion of 
nicotine to nomicotine, including the nicotine demethylase 
polypeptides set forth in SEQ ID NOS:2, 5, 7-11, 13, 16-21 
30 and 23-24. Generally, variants of a particular polynucleotide 
of the invention, e.g., the polynucleotide sequence of SEQ ID 
N0:3 or the polynucleotide sequence encoding the amino 
acid sequence set forth in SEQ ID N0:2 and 5-24, will have 
at least about 40%,45%, 50%, 55%, 60%, 65%,70%,75%, 
35 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 
98%, 99% or more sequence identity to that particular poly-
nucleotide as determined by sequence alignment programs 
and parameters described elsewhere herein. 
Variants of a particular polynucleotide of the present inven-
40 tion (also referred to as the reference polynucleotide) can also 
be evaluated by comparison of the percent sequence identity 
between the polypeptide encoded by the reference polynucle-
otide and the polypeptide encoded by a variant polynucle-
otide. Percent sequence identity between any two polypep-
45 tides can be calculated using sequence alignment programs 
and parameters described elsewhere herein. Where any given 
pair of polynucleotides of the invention is evaluated by com-
parison of the percent sequence identity shared by the two 
polypeptides they encode, the percent sequence identity 
50 between the two encoded polypeptides is at least about 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
sequence identity. A variant polypeptide of the present inven-
tion can include a polypeptide having a serine at position 458, 
55 an asparagine at position 364 of the cytochrome P450 
polypeptide, a stop codon at position 329 of the cytochrome 
P450 or any combination thereof, where the numbering cor-
responds to SEQ ID N0:13. 
Furthermore, the polynucleotides of the invention can be 
60 used to isolate corresponding cytochrome P450 sequences 
from other organisms, particularly other plants, more particu-
larly other members of the Nicotiana genus. PCR, hybridiza-
tion and other like methods can be used to identifY such 
sequences based on their sequence homology to the 
65 sequences set forth herein. Sequences isolated based on their 
sequence identity to the nucleotide sequences set forth herein 
or to variants and fragments thereof are encompassed by the 
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present invention. Such sequences include sequences that are 
orthologs of the disclosed sequences. 
As used herein, "orthologs" means genes derived from a 
common ancestral gene that are found in different species as 
16 
in 0.5x to 1xSSC at 55 to 60° C. Exemplary high stringency 
conditions include hybridization in 50% formamide, 1 M 
NaCl, 1% SDS at 37° C. and a wash in 0.1xSSC at 60 to 65° 
C. Optionally, wash buffers may comprise about 0.1% to 
about 1% SDS. Duration of hybridization is generally less 
than about 24 hours, usually about 4 to about 12 hours. The 
duration of the wash time will be at least a length of time 
sufficient to reach equilibrium. 
Preferably, stringency conditions include hybridization in 
a result of speciation. Genes found in different species are 
considered orthologs when their nucleotide sequences and/or 
their encoded protein sequences share at least 60%, 70%, 
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 
97%, 98%, 99% or greater sequence identity. Functions of 
orthologs are often highly conserved among species. Thus, 
isolated polynucleotides that encode for a nicotine demethy-
lase polypeptide that is involved in the nicotine-to-nomico-
tine metabolic conversion and which hybridize under strin-
gent conditions to the cytochrome P450 sequences disclosed 
herein, or to variants or fragments thereof, are encompassed 
by the present invention. Such sequences can be used in the 
methods of the present invention to inhibit expression of 
nicotine demethylase polypeptides that are involved in the 
metabolic conversion of nicotine to nomicotine in plants. 
10 a solution containing 5xSSC, 0.5% SDS, 5xDenhardt's, 0.45 
ug/ul poly A RNA, 0.45 ug/ul calf thymus DNA and 50% 
formamide at 42° C., and at least one post-hybridization wash 
in a solution comprising from about O.OlxSSC to about 
1xSSC. The duration of hybridization is from about 14 to 
15 about 16 hours. 
Using PCR, oligonucleotide primers can be designed for 20 
use in PCR reactions to amplifY corresponding DNA 
sequences from eDNA or genomic DNA extracted from any 
plant of interest. Methods for designing PCR primers and 
PCR cloning are generally known in the art and are disclosed 
in Sambrook eta!. (1989) Molecular cloning: a laboratory 25 
manual (2d ed, Cold Spring Harbor Laboratory Press, Plain-
view, N.Y.). Iunis eta!., eds. (1990)PCRprotocols: a guide to 
methods and applications (Academic Press, New York); Innis 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and tem-
perature of the final wash solution. For DNA-DNA hybrids, 
the T m can be approximated from the equation ofMeinkoth & 
Wahl (1984)Anal. Biochem. 138:267-284: T m =81.5° C.+16.6 
(log M)+0.41 (% GC)-0.61 (% form)-500/L; where M is the 
molarity of monovalent cations, % GC is the percentage of 
guanosine and cytosine nucleotides in the DNA, %form is the 
percentage of formamide in the hybridization solution, and L 
is the length of the hybrid in base pairs. The T m is the tem-
perature (under defined ionic strength and pH) at which 50% 
of a complementary target sequence hybridizes to a perfectly 
matched probe. T m is reduced by about 1 o C. for each 1% of 
mismatching; thus, Tm, hybridization, and/or wash condi-
tions can be adjusted to hybridize to sequences of the desired 
identity. For example, if sequences with ;;,:90% identity are 
sought, the T m can be decreased 10° C. Generally, stringent 
conditions are selected to be about so C. lower than the 
thermal melting point (T m) for the specific sequence and its 
& Gelfand, eds. (1995) PCR strategies (Academic Press, 
New York); and Innis & Gelfand, eds. (1999) PCR methods 30 
manual (Academic Press, New York). Known methods of 
PCR include, but are not limited to, methods using paired 
primers, nested primers, single specific primers, degenerate 
primers, gene-specific primers, vector-specific primers, par-
tially mismatched primers and the like. 35 complement at a defined ionic strength and pH. However; 
severely stringent conditions can utilize a hybridization and/ 
or wash at 1, 2, 3 or 4 o C. lower than the thermal melting point 
(T m); moderately stringent conditions can utilize a hybridiza-
tion and/or wash at 6, 7, 8, 9 or 10° C. lower than the thermal 
Hybridization techniques involve the use of all or part of a 
known polynucleotide as a probe that selectively hybridizes 
to other corresponding polynucleotides present in a popula-
tion of cloned genomic DNA fragments or eDNA fragments 
(i.e., genomic or eDNA libraries) from a chosen organism. 40 melting point (T m); low stringency conditions can utilize a 
hybridizationandlorwashat 11, 12, 13, 14, 15 or 20° C.lower 
than the thermal melting point (Tm). Using the equation, 
hybridization and wash compositions, and desired T m' those 
Hybridization may be carried out under stringent condi-
tions. As used herein, "stringent conditions" or "stringent 
hybridization conditions" means conditions under which a 
probe will hybridize to its target sequence to a detectably 
greater degree than to other sequences (e.g., at least two-fold 45 
over background). Stringent conditions are sequence-depen-
dent and will be different in different circumstances. By con-
trolling the stringency of the hybridization and/or washing 
conditions, target sequences that are 100% complementary to 
the probe can be identified (homologous probing). Alterna- 50 
tively, stringency conditions can be adjusted to allow some 
mismatching in sequences so that lower degrees of similarity 
are detected (heterologous probing). Generally, a probe is less 
than about 1000 nucleic acids in length, optimally less than 
500 nucleic acids in length. 
of ordinary skill will understand that variations in the strin-
gency of hybridization and/or wash solutions are inherently 
described. If the desired degree of mismatching results in a 
T m' ofless than 45° C. (aqueous solution) or 32° C. (forma-
mide solution), it is optimal to increase the sse concentration 
so that a higher temperature can be used. An extensive guide 
to the hybridization of nucleic acids is found in Tij ssen (1993) 
Laboratory techniques in biochemistry and molecular biol-
ogy-hybridization with nucleic acid probes, Part I, Chapter 2 
(Elsevier, New York); andAusubel eta!., eds. (1995) Current 
protocols in molecular biology, Chapter 2 (Greene Publish-
55 ing and Wiley-Interscience, New York). See also, Sambrook 
eta!. (1989) Molecular cloning: a laboratory manual (2d ed., 
Cold Spring Harbor Laboratory Press, Plainview, N.Y.). 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 
7.0 to 8.3 and the temperature is at least about 30° C. Stringent 
conditions may also be achieved with the addition of desta- 60 
bilizing agents such as formamide. Exemplary low stringency 
conditions include hybridization with a buffer solution of30 
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl 
sulphate) at 37° C., and a wash in 1x to 2xSSC (20xSSC=3.0 
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary 65 
moderate stringency conditions include hybridization in 40 to 
45% formamide, 1.0 MNaCl, 1% SDS at 37° C., and a wash 
Hybridization probes may be genomic DNA fragments, 
eDNA fragments, RNA fragments or other oligonucleotides, 
and may be labeled with a detectable group such as 32P, or any 
other delectable marker. For example, probes for hybridiza-
tion can be made by labeling synthetic oligonucleotides based 
on the cytochrome P450 polynucleotides sequences of the 
present invention. Methods for preparation of probes for 
hybridization and for construction of eDNA and genomic 
libraries are generally known in the art and are disclosed in 
Sambrook et a!., supra. 
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For example, the cytochrome P430 polynucleotides dis-
closed herein, or one or more portions thereof, may be used as 
probes capable of specifically hybridizing to corresponding 
cytochrome P450 polynucleotides and messenger RNAs. To 
achieve specific hybridization under a variety of conditions, 
such probes include sequences that are unique among cyto-
chrome P450 polynucleotide sequences or unique to one of 
the cytochrome P450 polynucleotide sequences, including 
upstream regions 5' to the coding sequence and downstream 
regions 3' to the coding sequence and an intron region, and are 
optimally at least about 10 contiguous nucleotides in length, 
more optimally at least about 20 contiguous nucleic acids in 
length, more optimally at least about 50 contiguous nucleic 
acids in length, more optimally at least about 75 contiguous 
nucleic acids in length, and more optimally at least about 100 
contiguous nucleic acids in length. Such probes may be used 
to amplify corresponding cytochrome P450 polynucleotides. 
This technique may be used to isolate additional coding 
sequences or mutations from a desired plant or as a diagnostic 
assay to determine the presence of coding sequences in a 
plant. Hybridization techniques include hybridization screen-
ing of plated DNA libraries (either plaques or colonies; see, 
e.g., Sambrook eta!., supra. 
As used herein, with respect to the sequence relationships 
between two or more polynucleotides or polypeptides, the 
term "reference sequence" means a defined sequence used as 
a basis for sequence comparison. A reference sequence may 
be a subset or the entirety of a specified sequence; for 
example, as a segment of a full-length eDNA or gene 
sequence, or the complete eDNA or gene sequence. 
As used herein, "comparison window" means a contiguous 
and specified segment of a polynucleotide sequence, where 
the polynucleotide sequence in the comparison window may 
comprise additions or deletions (i.e., gaps) compared to the 
reference sequence (which does not comprise additions or 
deletions) for optimal aligmnent of the two polynucleotides. 
Generally, a comparison window is at least 20 contiguous 
nucleic acids in length, and optionally can be 30, 40, 50 or 100 
contiguous nucleic acids or longer. Those of skill in the art 
understand that to avoid a high similarity to a reference 
sequence due to inclusion of gaps in the polynucleotide 
sequence a gap penalty is typically introduced and is sub-
tracted from the number of matches. 
Methods of alignment of sequences for comparison are 
well known in the art. Thus, the determination of percent 
sequence identity between any two sequences can be accom-
plished using a mathematical algorithm. Non-limiting 
examples of such mathematical algorithms are the algorithm 
of Myers & Miller (1988) CABIOS 4:11-17; the local align-
ment algorithm of Smith eta!. (1981 )Adv. Appl. Math. 2:482; 
the global alignment algorithm of Needleman & Wunsch 
(1970) J. Mol. Biol. 48:443-453; the search-for-local align-
ment method of Pearson & Lipman (1988) Proc. Nat!. A cad. 
Sci. 85:2444-2448; the algorithm of Karlin &Altschul (1990) 
Proc. Nat!. Acad. Sci. USA 872264, modified as in Karlin & 
Altschul (1993) Proc. Nat!. Acad. Sci. USA 90:5873-5877. 
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chul eta!. (1997) Nucleic Acids Res. 25:3389. Alternatively, 
PSI-BLAST (in BLAST 2.0) can be used to perform an iter-
ated search that detects distant relationships between mol-
ecules. See Altschul et a!. (1997) supra. When utilizing 
BLAST, Gapped BLAST, PSI-BLAST, the default param-
eters of the respective programs (e.g., BLASTN for nucle-
otide sequences, BLASTX for proteins) can be used. Align-
ment may also be performed manually by inspection. 
The sequence identity/similarity values provided herein 
10 were calculated using the BLASTX (Altschul eta!. (1997) 
supra), Clustal W (Higgins eta!. (1994) Nucleic Acids Res. 
22:4673-4680), and GAP (University of Wisconsin Genetic 
Computing Group software package) algorithms using 
default parameters. The present invention also encompasses 
15 the use of any equivalent program thereoffor the analysis and 
comparison of nucleic acid and protein sequences. By 
"equivalent program" is intended any sequence comparison 
program that, for any two sequences in question, generates an 
alignment having identical nucleotide or amino acid residue 
20 matches and an identical percent sequence identity when 
compared to the corresponding alignment generated by 
BLASTX. Clustal W, or GAP. 
For purposes of the foregoing discussion of variant nucle-
otide and polypeptide sequences encompassed by the present 
25 invention, "sequence identity" or "identity" in the context of 
two polynucleotides or polypeptide sequences makes refer-
ence to the residues in the two sequences that are the same 
when aligned for maximum correspondence over a specified 
comparison window. When percentage of sequence identity 
30 is used in reference to proteins it is recognized that residue 
positions which are not identical often differ by conservative 
amino acid substitutions, where amino acid residues are sub-
stituted for other amino acid residues with similar chemical 
properties (e.g., charge or hydrophobicity) and therefore do 
35 not change the functional properties of the molecule. When 
sequences differ in conservative substitutions, the percent 
sequence identity may be adjusted upwards to correct for the 
conservative nature of the substitution. Sequences that differ 
by such conservative substitutions are said to have "sequence 
40 similarity" or "similarity." Means for malting this adjustment 
are well known to those of skill in the art. Typically this 
involves scoring a conservative substitution as a partial rather 
than a full mismatch, thereby increasing the percentage 
sequence identity. Thus, for example, where an identical 
45 amino acid is given a score of 1 and a non-conservative 
substitution is given a score of zero, a conservative substitu-
tion is given a score between zero and 1. The scoring of 
conservative substitutions is calculated, e.g., as implemented 
in the program PC/GENE (Intelligenetics; Mountain View, 
50 Calif.). 
As used herein, "percentage of sequence identity" means 
the value determined by comparing two optimally aligned 
sequences over a comparison window, where the portion of 
the polynucleotide sequence in the comparison window may 
55 comprise additions or deletions (i.e., gaps) as compared to the 
reference sequence (which does not comprise additions or 
deletions) for optimal alignment of the two sequences. The 
percentage is calculated by determining the number of posi-
tions at which the identical nucleic acid base or amino acid 
The BLAST programs of Altschul eta!. (1990) J. Mol. Biol. 
215:403 are based on the algorithm of Karlin & Altschul 
(1990) supra. BLAST nucleotide searches can be performed 
with the BLASTN program, score=100, wordlength=12, to 60 
obtain nucleotide sequences homologous to a nucleotide 
sequence encoding a protein of the invention. BLAST protein 
searches can be performed with the BLASTX program, 
score=50. wordlength=3, to obtain amino acid sequences 
homologous to a protein or polypeptide of the invention. To 65 
obtain gapped alignments for comparison purposes, Gapped 
BLAST (in BLAST 2.0) can be utilized as described inAlts-
residue occurs in both sequences to yield the number of 
matched positions, dividing the number of matched positions 
by the total number of positions in the window of comparison, 
and multiplying the result by 100 to yield the percentage of 
sequence identity. 
Thus, cytochrome P450 polynucleotide and polypeptide 
sequences can be identified using the sequences provided 
herein. Such methods include obtaining a polynucleotide or 
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polypeptide sequence at least 80%, 85%, 90%, 95%, 98% or 
99% sequence identity with the polynucleotide sequence of 
SEQ ID NO: 1, 3 or 4 or a complement or fragment thereof, or 
20 
Furthermore, a fragment of a cytochrome P450 polynucle-
otide or polypeptide can contain contiguous nucleotides from 
about 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the entire 
gene. Alternatively stated, a fragment of a cytochrome P450 
polynucleotide or polypeptide can be between about 
5%-about 80%, between about 1 0%-about 70%, between 
about 10%-about 60%, between about 10%-about 50%, 
between about 25%-about 60%, between about 25%-about 
50%, between about 40%-about 60%, between about 40%-
a polypeptide sequence of SEQ ID N0:2 or 5-24. A preferred 
embodiment includes a polypeptide corresponding to SEQ ID 5 
NO: 13 that has a serine at position 458 or an asparagine at 
position 364 of the cytochrome P450 polypeptide, or a stop 
codon at position 329 of the cytochrome P450, or a combi-
nation thereof, where the numbering corresponds to SEQ ID 
N0:13. 10 about 80%, between about 50%-about 90% of the length of an 
entire cytochrome P450. Expression Cassettes for Use in the Methods oflnvention 
Expression cassettes of the present invention include those 
that encompass additional domains that modulate the level of 
expression, the developmental timing of expression, or tissue 
Compositions of the present invention further include 
expression cassettes comprising inhibitory sequences 
capable of inhibiting expression or function of a nicotine 
demethylase polypeptide involved in the conversion of nico-
tine to nomicotine in a Nicotiana plant or plant part thereof, 
where the inhibitory sequences are operably linked to a pro-
moter that is functional in a plant cell. In this manner, expres-
sion cassettes comprising all or part of the sequence set forth 
15 type that expression occurs in (e.g., AU Patent No. AU-A-
77751/94 and U.S. Pat. Nos. 5,466,785 and 5,635,618). Pro-
moters can be selected based on the desired outcome. The 
nucleic acids of the present invention can be combined with 
in SEQ ID NO: 1, 3 or 4 or encoding SEQ ID N0:2 or 5-24, a 20 
complement or fragment thereof, or sequences sharing sub-
stantial sequence identity to such sequences, or a complement 
or fragment thereof, operably linked to a promoter that is 
functional in a plant cell are constructed for use in the gene-
silencing methods of the present invention described herein 25 
below. Such sequences are referred to herein as "inhibitory 
sequences" or "inhibitory polynucleotide sequences," as they 
are capable of being expressed as an RNA molecule that 
inhibits expression (i.e., transcription and/or translation) of 
the target cytochrome P450 polypeptide, for example, the 30 
polypeptide set forth in SEQ ID N0:2 or 5-24 and variants 
thereof, where the variant polypeptides have substantial 
sequence identity to these disclosed cytochrome P450 
polypeptides. Such variants may or may not be involved in the 
metabolic conversion of nicotine to nornicotine in a plant. 35 
Such sequences also include fragment sequences of the target 
cytochrome P450 polynucleotide or polypeptide. For 
example, a fragment sequence can include any portion of the 
cytochrome P450 sequence, including coding and non-cod-
ing sequence (e.g., 5' UTR, intron, and 3' UTR sequences), 40 
and can include fragments between 100 and about 350 
nucleic acids, between about 125 and about 300 nucleic acids, 
or between about 125 and about 27 5 nucleic acids. Preferably, 
a fragment of nicotine demethylase can be between about 20 
and about 420, about 30 and about 420, between about 40 and 45 
about 320, between about 50 and about 200, between about 50 
and about 400, between about 50 and about 420, between 
about 60 and about 320, about 70 and about 220, between 
about 100 and about 200, between about 100 and about 320, 
between about 150 and about 200, between about 150 and 50 
about 220, between about 150 and about 400, between about 
200 and about 300, or between about 300 and about 400 
contiguous nucleic acids. Alternatively, a fragment of a cyto-
chrome P450 can be about 100, about 150, about 200, about 
220, about 250, about 300, about 320, or about 350 contigu- 55 
ous nucleic acids in length. Alternatively yet, a cytochrome 
P450 fragment can be reduced in length by about 20, about 
40,about60,about80,about100,about120,about140,about 
160, about 180, about 200, about 220, about 240, about 260, 
about280,about290,about300,about320,about340,about 60 
360, about 380, about 400 contiguous nucleic acids compared 
to the full-length. For all of these cytochrome P450 frag-
ments, the truncation or deletion can start at the 5' end, start at 
the 3' end, or be internal to a cytochrome P450 or a cyto-
chrome P450 intron. For a cytochrome P450 intron fragment, 65 
the entire sequence of a cytochrome P450 intron can be SEQ 
IDN0:3. 
inducible, constitutive, pathogen- or wound-induced, envi-
ronmentally- or developmentally-regulated, cell- or tissue-
preferred promoter, or other promoters for expression in 
plants. 
Chemical-inducible promoters can be used to inhibit the 
expression of a cytochrome P450 that is involved in the meta-
bolic conversion of nicotine to nornicotine in a plant through 
the application of an exogenous chemical regulator. Chemi-
cal-inducible promoters are known in the art and include, but 
are not limited to, the tobacco PR-la promoter, which is 
activated by salicylic acid. Other chemical-inducible promot-
ers of interest include steroid-responsive promoters (see, e.g., 
the glucocorticoid-inducible promoter (Schena eta!. (1991) 
Proc. Nat!. Acad. Sci. USA 88:10421-10425; and McNellis et 
a!. (1998) Plant J. 14(2):247-257) and tetracycline-inducible 
promoters (see, e.g., Gatz et a!. (1991) Mol. Gen. Genet. 
227:229-237; and U.S. Pat. Nos. 5,814,618 and 5,789,156), 
each of which is incorporated herein by reference as if set 
forth in its entirety. 
Constitutive promoters include, e.g., the core promoter of 
the Rsyn7 promoter and outer constitutive promoters dis-
closed in U.S. Pat. No. 6,072,050; the core CaMV 35S pro-
moter (Odell et a!. (1985) Nature 313:810-812); ubiquitin 
(Christensen eta!. (1989) Plant Mol. Biol. 12:619-632; and 
Christensen et a!. (1992) Plant Mol. Biol. 18:675-689); 
pEMU (Last eta!. (1991) Theor. Appl. Genet. 81:581-588); 
MAS (Velten et a!. (1984) EMBO J. 3:2723-2730); ALS 
promoter (U.S. Pat. No. 5,659,026), and the like. Other con-
stitutive promoters include, e.g., those disclosed in U.S. Pat. 
Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 
5,399,680; 5,268,463; 5,608,142 and 6,177,611. 
Tissue-preferred promoters can be utilized to target expres-
sion of an inhibitory polynucleotide sequence of the present 
invention within a particular plant tissue. Tissue-preferred 
promoters include those disclosed in Yamamoto eta!. (1997) 
Plant J. 12(2):255-265; Kawamata eta!. (1997) Plant Cell 
Physiol. 38(7):792-803; Hansen et a!. (1997) Mol. Gen. 
Genet. 254(3):337-343; Russell eta!. (1997) Transgenic Res. 
6(2): 157 -168; Rinehart et a!. (1996) Plant Physiol. 112(3): 
1331-1341; Van Camp eta!. (1996) Plant Physiol. 112(2): 
525-535; Canevascini et a!. (1996) Plant Physiol. 112(2): 
513-524; Yamamoto eta!. (1994) Plant Cell Physiol. 35(5): 
773-778; Lam (1994) Results Probl. Cell Differ. 20:181-196; 
Orozco eta!. (1993) Plant Mol. Biol. 23(6): 1129-1138; Mat-
suoka eta!. (1993) Proc Nat!. Acad. Sci. USA 90(20):9586-
9590; andGuevara-Garcia eta!. (1993) PlantJ. 4(3):495-505. 
Of particular interest herein are leaf preferred promoters 
that provide for expression predominately in leaf tissues. See, 
e.g., Yamamoto eta!. (1997)Plant J. 12(2):255-265; Kwonet 
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a!. (1994)Plant Physiol. 105:357-67; Yamamoto eta!. (1994) 
Plant Cell Physiol. 35(5):773-778; Gator eta!. (1993) Plant 
J. 3:509-18; Orozco eta!. (1993)PlantMol. Biol. 23(6):1129-
1138; Baszczynski eta!. (1988) Nucl. Acid Res. 16:4732; 
Mitra et a!. (1994) Plant Molecular Biology 26:35-93; 5 
Kayaya eta!. (1995) Molecular and General Genetics 248: 
668-674; and Matsuoka eta!. (1993) Proc. Nat!. Acad. Sci. 
USA 90(20):9586-9590. Senecence-regulated et a!. (1998) 
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino 
(1997) Plant Physiol. 113:313-319; SAG 15 (Gan (1995) 10 
"Molecular Characterization and Genetic Manipulation of 
Plant Senescence," Ph.D. Thesis, University of Wisconsin, 
Madison); SEN! (Oh eta!. (1996) Plant Mol. Biol. 30:739-
7 54; promoter of a senescence-specific gene for expression of 
IPT (Gan andAmasino 91995) Science 270:1986-1988); and 15 
the like (see, e.g., Or eta!. (1999) Plant Celli I: 1073-1080; 
and McCabe eta!. (2001) Plant Physiol. 127:505-516). 
Expression cassettes of the present invention can include 5' 
leader sequences that can act to enhance translation. Transla-
tion leaders are known in the art and include, but are not 20 
limited to, picornavirus leaders, e.g., EMCV leader (En-
cephalomyocarditis 5' noncoding region; Elroy-Stein et a!. 
(1989) Proc. Nat!. Acid. Sci. USA 86:6126-6130); potyvirus 
leaders, e.g., TEV leader (Tobacco Etch Virus; Gallie et a!. 
(1995) Gene 165(2):233-238), MDMV leader (Maize Dwarf 25 
Mosaic Virus; Virology 154:9-20), and human immunoglo-
bulinheavy-chain binding protein (BiP; Macejak eta!. (1991) 
Nature 353:90-94); untranslated leader from the coat protein 
mRNA of alfalfa mosaic virus (AMY RNA 4; Job ling et a!. 
(1987) Nature 325:622-625); tobacco mosaic virus leader 30 
(TMV; Gallie eta!. (1989) in Molecular biology of RNA, ed. 
Cech (Liss, New York), pp. 237-256); and maize chlorotic 
mottle virus leader (MCMV; Lamme! eta!. (1991) Virology 
81:382-385). See also, Della-Cioppa et a!. (1987) Plant 
Physiol. 84:965-968. Other methods known to enhance trans- 35 
lation also can be utilized. 
Methods for Inhibiting Expression or Function of a Nicotine 
Demethylase 
22 
5% of the protein level of the same cytochrome P450 
polypeptide in a plant that is not a mutant or that has not been 
genetically modified to inhibit the expression of that cyto-
chrome P450 polypeptide and which has been cultured and 
harvested using the same protocols. The expression level of 
the cytochrome P450 polypeptide may be measured directly, 
for example, by assaying for the level of the cytochrome P450 
transcript or cytochrome P450 polypeptide expressed in the 
Nicotiana plant or plant part, or indirectly, e.g., by measuring 
the conversion of nicotine to nornicotine in the Nicotiana 
plant or plant part. Methods for monitoring expression level 
of a polypeptide are known in the art, and include, but are not 
limited to, Northern blot analysis and RNA differentiation 
assays. Methods for determining the activity of a targeted 
cytochrome P450 polypeptide in converting nicotine to nor-
nicotine are known in the art and described elsewhere herein 
below, and include, but are not limited to, alkaloid analysis 
using gas chromatography. 
In some instances, the activity of one or more cytochrome 
P450 polypeptides is reduced or eliminated by transforming a 
plant or plant part with an expression cassette comprising a 
polynucleotide encoding a polypeptide that inhibits the activ-
ity of one or more cytochrome P450 polypeptides of the 
present invention. A number of approaches have been used to 
combine transgenes or mutations in one plant-including 
sexual crossing, retransformation, co-transformation and the 
use of linked trans genes. A chimeric transgene with linked 
partial gene sequences can be used to coordinately suppress 
numerous plant endogenous genes. Constructs modeled on 
viral polyproteins can be used to simultaneously introduce 
multiple coding genes into plant cells. For a review, see Hal-
pin eta!., Plant Mol. Biol. 47:295-310 (2001). A plant having 
a mutation in CYP82E4v2 that inhibits the nicotine demethy-
lase activity in senescent leaves can be crossed with a plant 
having a mutation in CYP83E5v2 that inhibits nicotine dem-
ethylase in green leaves to produce a plant with conversion 
levels lower than about 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or 
0.7%. Alternatively, a plant having one or more mutations in 
CYP82E4v2 atposition458, 364,38,201, 169,459,296,427, Methods of reducing the concentration, content and/or 
activity of a cytochrome P450 polypeptide of the present 
invention in a Nicotiana plant or plant part, particularly the 
leaf tissue, are provided. Many methods may be used, alone or 
in combination, to reduce or eliminate the activity of a cyto-
chrome P450 polypeptide of the present invention, more par-
ticularly, the CYP82E5v2 nicotine demethylase. In addition, 
combinations of methods may be employed to reduce or 
eliminate the activity of two or more different cytochrome 
P450 polypeptides, more particularly the CYP82E5v2 and 
CYP82E4v2 nicotine demethylases. Preferably, the 
CYP82E5v2 is a polypeptide with at least one amino acid 
mutation in SEQ ID N0:2 that negatively affects conversion 
in green leaves and the CYP82E4v2 has the sequence set forth 
40 329, 376 or 171 can be crossed with a plant having one or 
more mutations in CYP83E5v2 at position 235, 449, 174, 
410, 224, 72 or 143 to produce a plant with conversion levels 
lower than 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or 0.7%. Alterna-
tively still, a plant having one or more mutations in 
45 CYP82E4v2 at position 458, 364 or 329 can be crossed with 
a plant having one or more mutations in CYP83E5v2 at 
position235, 449, 174,410,224,72, or 143 to produce a plant 
with conversion levels lower than 0.2%, 0.3%, 0.4%, 0.5%, 
0.6%, or 0.7%. A particularly preferred conversion level of 
in SEQ ID NO: 13 with at least one amino acid mutation that 
negatively affects conversion in senescent leaves. 
50 nicotine to nornicotine can be between 0.05%-0.4%, between 
0.1-0.6%, between 0.1%-0.3%, between 0.1%-0.5%, 
between 0.1 %-0.4%, between 0.1 %-0.7%, or between 0.1%-
1.0%. Any mutation of a polynucleotide of the present inven-
tion that results in a truncation of the CYP83E4v2 or 
In accordance with the present invention, the expression of 55 
a cytochrome P450 polypeptide of the present invention is 
inhibited if the protein level of the cytochrome P450 polypep-
tide is statistically lower than the protein level of the same 
cytochrome P450 polypeptide in a plant that has not been 
genetically modified or mutagenized to inhibit the expression 60 
of that cytochrome P450 polypeptide, and where these plants 
have been cultured and harvested using the same protocols. In 
particular embodiments of the invention, the protein level of 
the cytochrome P450 polypeptide in a modified plant accord-
ing to the invention is less than 95%, less than 90%, less than 65 
80%, less than 70%, less than 60%, less than 50%, less than 
40%, less than 30%, less than 20%, less than 10%, or less than 
CYP83E5v2 polypeptide before a conserved heme-binding 
motif will inhibit the enzyme and can be used in a cross 
described above. The domains of cytochrome P450 proteins 
are known in the art. See, e.g., Xu et a!. (2007) Physiologia 
Plantarum 129:307-319, incorporated herein by reference as 
if set forth in its entirety. By crossing plants having a non-
functional or inhibited CYP82E4v2 gene, a nonfunctional or 
inhibited CYP82E5v2 gene, or nonfunctional or inhibited 
CYP82E4v2 and CYP82E5v2 genes, nornicotine levels can 
be reduced in a tobacco plant. 
The activity of a nicotine demethylase polypeptide in con-
verting nicotine to nornicotine in a Nicotiana plant or plant 
part is inhibited according to the present invention if this 
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conversion actJv1ty is statistically lower than conversion 
activity of the same cytochrome P450 polypeptide in a Nic-
otiana plant or plant part that has not been genetically modi-
fied to inhibit the conversion activity of that cytochrome P450 
polypeptide and that has been cultured and harvested using 
the same protocols. In particular embodiments, activity of a 
cytochrome P450 polypeptide in converting nicotine to nor-
nicotine in a modified Nicotiana plant or plant part according 
to the invention is inhibited if the activity is less than 95%, 
less than 90%, less than 80% less than 70%, less than 60%, 
less than 50%, less than 40%, less than 30%, less than 20% 
less than 10%, less than 5%, less than 2% or less than 1% of 
the conversion activity of the same cytochrome P450 
polypeptide in a Nicotiana plant that that has not been geneti-
cally modified to inhibit the expression of that nicotine dem-
ethylase polypeptide and that has been cultured and harvested 
using the same protocols. The activity of a nicotine demethy-
lase polypeptide in converting nicotine to nomicotine in a 
Nicotiana plant or plant part is eliminated according to the 
invention when it is not detectable by the assay methods 
known in the art or described herein. Methods of determining 
the activity of a cytochrome P450 polypeptide in converting 
nicotine to nomicotine in a Nicotiana using gas chromatog-
raphy are disclosed in the examples below. 
In specific embodiments, a cytochrome P450 inhibitory 
polynucleotide or nicotine demethylase mutation described 
herein is introduced into a Nicotiana plant or plant part. 
Subsequently, a Nicotiana plant or plant part having the intro-
duced inhibiting polynucleotide of the present invention is 
selected using methods known to those of skill in the art 
including, but not limited to, Southern blot analysis, DNA 
sequencing, PCR analysis or phenotypic analysis. A poly-
nucleotide or polypeptide sequence of the present invention 
includes full-length polynucleotide or polypeptide 
sequences, truncated polynucleotide or polypeptide 
sequences, fragments of polynucleotide or polypeptide 
sequences, variants of polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense-
oriented nucleotide sequences, the complement of a sense- or 
antisense-oriented nucleotide sequence, inverted regions of 
nucleotide sequences, hairpins of nucleotide sequences, 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. A 
plant or plant part altered or modified by the foregoing is 
grown under plant-forming conditions for a time sufficient to 
modulate the concentration and/or activity of polypeptides of 
the present invention in the plant. Plant forming conditions 
are well known in the art and discussed briefly elsewhere 
herein. 
A transformed tobacco plant containing a nicotine dem-
ethylase inhibitory polynucleotide sequence described herein 
has a reduced level of conversion of nicotine to nornicotine. In 
particular embodiments, conversion of nicotine to nomico-
tine in a tranformed tobacco plant or plant part according to 
the invention is less than 95%, less than 90%, less than 80% 
less than 70%, less than 60%, less than 50%, less than 40%, 
less than 30%, less than 20%, less than 10%, less than 5%, 
less than 2% or less than 1% of the conversion in a tobacco 
plant that that has not been genetically modified to inhibit the 
expression of that nicotine demethylase polypeptide and with 
has been cultured and harvested using the same protocols. In 
some instances, the transformed tobacco plant is a converter 
tobacco plant. Alternatively, the transformed tobacco plant is 
a nonconverter tobacco plant. Alternatively still, the trans-
formed tobacco plant has a conversion rate lower than the rate 
observed in commercial non-converter tobacco plants. 
24 
The level and/or activity of the polypeptide may be modu-
lated by employing a polynucleotide that is not capable of 
directing, in a transformed plant, the expression of a protein 
or an RNA. For example, the polynucleotides of the invention 
may be used to design polynucleotide constructs that can be 
employed in methods for altering or mutating a genomic 
nucleotide sequence in an organism. Such polynucleotide 
constructs include, but are not limited to, RNA: DNA vectors, 
RNA:DNA mutational vectors, RNA:DNA repair vectors, 
10 mixed-duplex oligonucleotides, self-complementary RNA: 
DNA oligonucleotides and recombinogenic oligonucleo-
bases. Such nucleotide constructs and methods of use are 
known in the art. See, U.S. Pat. Nos. 5,565,350; 5,731,181; 
5,756,325; 5,760,012; 5,795,972 and 5,871,984; each of 
15 which is incorporated herein by reference as if set forth in its 
entirety. See also, International Patent Application Publica-
tion Nos. WO 98/149350, WO 99/107865 and WO 
99/125921; and Beetham eta!. (1999) Proc. Nat!. Acad. Sci. 
USA 96:8774-8778; each of which is incorporated herein by 
20 reference as if set forth in its entirety. 
The methods of the present invention do not depend on the 
incorporation of the entire nicotine demethylase inhibitory 
polynucleotide into the genome, only that the Nicotiana plant 
or plant part thereof is altered as a result of the introduction of 
25 this inhibitory polynucleotide into a cell. As such, the genome 
may be altered following the introduction of the nicotine 
demethylase inhibitory polynucleotide into a cell. For 
example, the inhibitory polynucleotide, or any part thereof, 
may incorporate into the genome of the plant. Alterations to 
30 the genome include, but are not limited to, additions, dele-
tions and substitutions of nucleotides into the genome. While 
the methods of the present invention do not depend on addi-
tions, deletions and substitutions of any particular number of 
nucleotides, it is recognized that such additions, deletions 
35 and/or substitutions comprise at least one nucleotide. 
Further, one can reduce the level and/or activity of a nico-
tine demethylase sequence by eliciting the effects of the 
sequence only during certain developmental stages and to 
switch the effect off in other stages where expression is no 
40 longer desirable. Control of nicotine demethylase expression 
can be obtained via the use of inducible or tissue-preferred 
promoters. Alternatively, the gene could be inverted or 
deleted using site-specific recombinases, transposons or 
recombination systems, which would also tum on or off 
45 expression of the cytochrome P450 sequence. 
According to the present invention, changes in levels, 
ratios, activity or distribution of cytochrome P450 polypep-
tides of the present invention, or changes in Nicotiana plant or 
plant part phenotype, particularly reduced accumulation of 
50 nornicotine and its carcinogenic metabolite, NNN, can be 
measured by comparing a subject plant or plant part to a 
control plant or plant part, where the subject plant or plant part 
and the control plant or plant part have been cultured and/or 
harvested using the same protocols. As used herein, a subject 
55 plant or plant part is one in which genetic alteration, such as 
transformation, has been affected as to the nicotine demethy-
lase polypeptide of interest, or is a Nicotiana plant or plant 
part that is descended from a Nicotiana plant or plant part so 
altered and which comprises the alteration. A control plant or 
60 plant part provides a reference point for measuring changes in 
phenotype of the subject plant or plant part. The measurement 
of changes in phenotype can be measured at any time in a 
plant or plant part, including during plant development, 
senescence, or after curing. In other embodiments, the mea-
65 surement of changes in phenotype can be measured in plants 
grown under any conditions, including from plants grown in 
growth chamber, greenhouse, or in a field. In one embodi-
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ment, changes in phenotype can be measured by determining 
the nicotine to nomicotine conversion rate. In a preferred 
embodiment, conversion can be measured by dividing the 
percentage of nornicotine (as a percentage of the total tissue 
weight) by the sum of the percentage nicotine and nornicotine 
(as percentages of the total tissue weight) and multiplying by 
100. 
26 
For cosuppression, an expression cassette is designed to 
express an RNA molecule corresponding to all or part of a 
messenger RNA encoding a cytochrome P450 polypeptide of 
interest (for example, a cytochrome P450 polypeptide com-
prising the sequence set forth in SEQ ID N0:2 or 5-24 or a 
sequence having substantial sequence identity to SEQ ID 
N0:2 or 5-24) in the "sense" orientation. Over-expression of 
the RNA molecule can result in reduced expression of the 
native gene. Multiple plant lines transformed with the cosup-
According to the present invention, a control plant or plant 
part may comprise a wild-type Nicotiana plant or plant part, 
i.e., of the same genotype as the starting material for the 
genetic alteration that resulted in the subject plant or plant 
part. A control plant or plant part may also comprise a Nic-
otiana plant or plant part of the same genotype as the starting 
material but that has been transformed with a null construct 
(i.e., with a construct that has no known effect on the trait of 
interest, such as a construct comprising a selectable marker 
gene). Alternatively, a control plant or plan part may comprise 
10 pression expression cassette are then screened to identify 
those that show the greatest inhibition of nicotine demethy-
lase polypeptide expression. 
The polynucleotide used for cosuppression may corre-
spond to all or part of the sequence encoding a cytochrome 
15 P450 polypeptide or the present invention, all or part of the 5' 
and/or 3' untranslated region of a cytochrome P450 polypep-
tide transcript, or all or part of both the coding sequence and 
the untranslated regions of a transcript encoding a cyto-
chrome P450 polypeptide. In some embodiments where the 
a Nicotiana plant or plant part that is a non-transformed 
segregant among progeny of a subject plant or plant part, or a 
Nicotiana plant or plant part genetically identical to the sub-
ject plant or plant part but that is not exposed to conditions or 
stimuli that would induce suppression of the nicotine dem-
ethylase gene of interest. Finally, a control plant or plant part 
may comprise the subject plant or plant part itself under 
conditions in which the nicotine demethylase inhibitory 25 
sequence is not expressed. In all such cases, the subject plant 
20 polynucleotide comprises all or part of the coding region for 
a cytochrome P450 polypeptide of the present invention, the 
expression cassette can be designed to eliminate the start 
codon of the polynucleotide so that no polypeptide product 
will be transcribed. 
or plant part and the control plant or plant part are cultured 
and harvested using the same protocols. 
As described elsewhere herein, methods are provided to 
reduce or eliminate the activity and/or concentration of a 30 
nicotine demethylase polypeptide of the present invention by 
introducing into a Nicotiana plant or plant part a nicotine 
demethylase inhibitory polynucleotide sequence than is 
capable of inhibiting expression or function of a nicotine 
demethylase polypeptide that is involved in the metabolic 35 
conversion of nicotine to nomicotine. In some instances, the 
inhibitory sequence can be introduced by transformation of 
the plant or plant part such as a plant cell with an expression 
cassette that expresses a polynucleotide that inhibits the 
expression of the nicotine demethylase polypeptide. The 40 
polynucleotide may inhibit the expression of a nicotine dem-
ethylase polypeptide directly, by preventing translation of the 
nicotine demethylase polypeptide messenger RNA, or indi-
rectly, by encoding a polypeptide that inhibits the transcrip-
tion or translation of a nicotine demethylase polypeptide gene 45 
encoding a nicotine demethylase polypeptide. Methods for 
inhibiting or eliminating the expression of a gene product in 
Cosuppression may be used to inhibit the expression of 
plant genes to produce plants having undetectable levels for 
the polypeptides encoded by these genes or may also be used 
to inhibit the expression of multiple proteins in the same plant 
(e.g., Brain eta!. (2002) Plant Cell14:1417-1432; and U.S. 
Pat. No. 5,942,657). Methods for using cosuppression to 
inhibit the expression of endogenous genes in plants are 
described in Flavell eta!. (1994) Proc Nat!. Acad. Sci. USA 
91:3490-3496; Jorgensen et a!. (1996) Plant Mol. Biol. 
31:957-973; Johansen and Carrington (2001) Plant Physiol. 
126:930-938; Brain et a!. (2002) Plant Cell 14: 1417-1432; 
Stoutjesdijketal. (2002)Plant Physiol. 129:1723-1731; Yu et 
a!. (2003) Phytochemistry 63:753-763; and U.S. Pat. Nos. 
5,034,323; 5,283,184 and 5,942,657; each of which is incor-
porated herein by reference as if set forth in its entirety. The 
efficiency of cosuppression may be increased by including a 
poly-dT region in the expression cassette at a position 3' to the 
sense sequence and 5' of the polyadenylation signal. See, US 
Patent Application Publication No. 2002/0048814, incorpo-
rated herein by reference as if set forth in its entirety. Typi-
cally, such a nucleotide sequence has substantial sequence 
identity to the sequence of the transcript of the endogenous 
gene, preferably greater than about 65% sequence identity, 
more preferably greater than about 95% sequence identity, 
most preferably greater than about 99% sequence identity 
a plant are well known in the art, and any such method may be 
used in the present invention to inhibit the expression of 
nicotine demethylase polypeptides. 50 (e.g., U.S. Pat. Nos. 5,283,184 and 5,034,323; incorporated 
herein by reference as if set forth in its entirety). In other embodiments, the activity of a nicotine demethy-
lase polypeptide of the present invention may be reduced or 
eliminated by disrupting the gene encoding the nicotine dem-
ethylase polypeptide. The invention encompasses 
mutagenized plants that carry mutations in cytochrome P450 55 
genes, where the mutations reduce expression of the nicotine 
demethylase gene or inhibit the activity of an encoded nico-
tine demethylase polypeptide of the present invention. 
To obtain the desired plants, a Nicotiana plant or plant part 
can be transformed with an expression cassette that is capable 60 
of expressing a polynucleotide that inhibits the expression of 
a nicotine demethylase sequence. Such methods may include 
the use of sense suppression/cosuppression, antisense sup-
pression, double-stranded RNA (dsRNA) interference, hair-
pin RNA interference and intron-containing hairpin RNA 65 
interference, amplicon-mediated interference, ribozymes, 
and small interfering RNA or micro RNA. 
Inhibition of the expression of the cytochrome P450 
polypeptide of the present invention also can be obtained by 
antisense suppression. For antisense suppression, the expres-
sion cassette is designed to express an RNA molecule 
complementary to all or part of a messenger RNA encoding 
the cytochrome P450 polypeptide. Over-expression of the 
antisense RNA molecule can result in reduced expression of 
the native gene. Accordingly, multiple plant lines transformed 
with the antisense suppression expression cassette are 
screened to identifY those that show the greatest inhibition of 
nicotine demethylase polypeptide expression. 
The polynucleotide for use in antisense suppression may 
correspond to all or part of the complement of the sequence 
encoding the cytochrome P450 polypeptide, all or part of the 
complement of the 5' and/or 3' untranslated region of the 
cytochrome P450 polypeptide transcript, or all or part of the 
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complement ofboth the coding sequence and the untranslated 
regions of a transcript encoding the cytochrome P450 
polypeptide. In addition, the antisense polynucleotide may be 
fully complementary (i.e., 100% identical to the complement 
of the target sequence) or partially complementary (i.e., less 5 
than 100% identical to the complement of the target 
sequence) to the target sequence. 
Antisense suppression also can be used to inhibit the 
expression of multiple proteins in the same plant (e.g., U.S. 
Pat. No. 5,942,657). Furthermore, portions of the antisense 10 
nucleotides may be used to disrupt the expression of the target 
gene. Generally, sequences of at least 50 nucleic acids, 100, 
200, 300, 400, 450, 500, 550 nucleic acids, or greater may be 
used. Methods for using antisense suppression to inhibit the 
expression of endogenous genes in plants are described, e.g., 15 
in Liu eta!. (2002)Plant Physiol. 129:1732-1743; and U.S. 
Pat. Nos. 5,759,829 and 5,942,657; each of which is incor-
porated herein by reference as if set forth in its entirety. 
Efficiency of antisense suppression may be increased by 
including a poly-dT region in the expression cassette at a 20 
position 3' to the antisense sequence and 5' of the polyadeny-
lation signal. See, US Patent Application Publication No. 
2002/0048814, incorporated herein by reference as if set forth 
in its entirety. 
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P450 polypeptide. This method is described, for example, in 
U.S. Pat. No. 4,987,071, incorporated herein by reference as 
if set forth in its entirety. 
In other instances, inhibition of the expression of one or 
more nicotine demethylase polypeptides may be obtained by 
RNA interference by expression of a gene encoding a micro 
RNA (miRNA). miRNAs are regulatory agents consisting of 
about twenty-two ribonucleotides. miRNA are highly effi-
cient at inhibiting the expression of endogenous genes. See, 
e.g., Javier eta!. (2003) Nature 425:257-263, incorporated 
herein by reference as if set forth in its entirety. 
For miRNA interference, the expression cassette is 
designed to express an RNA molecule that is modeled on an 
endogenous miRNA gene. The miRNA gene encodes an 
RNA that forms a hairpin structure containing a 22-nucle-
otide sequence that is complementary to another endogenous 
gene (target sequence). For suppression of nicotine demethy-
lase polypeptide expression, the 22-nucleotide sequence is 
selected from a cytochrome P450 polypeptide transcript 
sequence and contains 22 nucleotides encoding this cyto-
chrome P450 polypeptide sequence in sense orientation and 
21 nucleotides of a corresponding antisense sequence that is 
complementary to the sense sequence. miRNA molecules are 
highly efficient at inhibiting the expression of endogenous 
25 genes, and the RNA interference they induce is inherited by 
subsequent generations of plants. 
For dsRNA interference, a sense RNA molecule like that 
described above for cosuppression and an antisense RNA 
molecule that is fully or partially complementary to the sense 
RNA molecule are expressed in the, same cell, resulting in 
inhibition of the expression of the corresponding endogenous 
messenger RNA. Expression of the sense and antisense mol-
ecules can be accomplished by designing the expression cas-
sette to comprise both a sense sequence and an antisense 
sequence for the target cytochrome P450 sequence. Alterna-
tively, separate expression cassettes may be used for the sense 
and antisense sequences. Multiple plant lines transformed 35 
with the dsRNA interference expression cassette or expres-
sion cassettes are then screened to identifY plant lines that 
show the greatest inhibition of expression of the targeted 
cytochrome P450 polypeptide. Methods for using dsRNA 
interference to inhibit the expression of endogenous plant 40 
genes are described in Waterhouse eta!. (1998) Pros. Nat!. 
Acad. Sci. USA 95:13939-13964; Liu et a!. (2002) Plant 
Physiol. 129:1732'-1743; and International Patent Applica-
tion Publication Nos. WO 99/149024, WO 99/153050, WO 
99/16163 1 and WO 00/149035; each of which is incorpo- 45 
rated herein by reference as if set forth in its entirety. 
Alternatively still, inhibition of the expression of one or 
more cytochrome P450 polypeptides may be obtained by 
hairpin RNA (hpRNA) interference or intron-containinghair-
30 pin RNA (ihpRNA) interference. These methods are highly 
efficient at inhibiting the expression of endogenous genes. 
See, Waterhouse & Helliwell (20013) Nat. Rev. Genet. 4:29-
38 and the references cited therein. 
Amplicon expression cassettes comprise a plant virus-de-
rived sequence that contains all or part of the target gene but 
generally not all of the genes of the native virus. The viral 
sequences present in the transcription product of the expres- 50 
sian cassette allow the transcription product to direct its own 
replication. The transcripts produced by the amplicon may be 
either sense or antisense relative to the target sequence (i.e., 
the messenger RNA for a cytochrome P450 polypeptide that 
is involved in the metabolic conversion of nicotine to norni- 55 
co tine). Methods of using amplicons to inhibit the expression 
of endogenous plant genes are described, e.g., in Angell & 
Baulcombe (1997) EMBO J. 16:3675-3684; Angell & Baul-
combe (1999) Plant J. 20:357-362; and U.S. Pat. No. 6,646, 
805, each of which is incorporated herein by reference as if set 60 
forth in its entirety. 
In some instances, the polynucleotide expressed by the 
expression cassette of the invention is catalytic RNA or has 
ribozyme activity specific for the messenger RNA of a cyto-
chrome P450 polypeptide described herein. Thus, the poly- 65 
nucleotide causes the degradation of the endogenous messen-
ger RNA, resulting in reduced expression of the cytochrome 
The expression cassette for hpRNA interference may also 
be designed such that the sense sequence and the antisense 
sequence do not correspond to an endogenous RNA in this 
embodiment, the sense and antisense sequence flank a loop 
sequence that comprises a nucleotide sequence correspond-
ing to all or part of the endogenous messenger RNA of the 
target gene. Thus, it is the loop region that determines the 
specificity of the RNA interference. See, e.g., International 
Patent Application Publication No. WO 02/00904, incorpo-
rated herein by reference as if set forth in its entirety. 
Transcriptional gene silencing (TGS) may be accom-
plished through use ofhpRNA constructs where the inverted 
repeat of the hairpin shares sequence identity with the pro-
moter region of a gene to be silenced. Processing of the 
hpRNA into short RNAs that can interact with the homolo-
gous promoter region may trigger degradation or methylation 
to result in silencing (Aufsatz eta!. (2002) Proc. Nat!. A cad. 
Sci. 99: 16499-16506; and Mette et a!. (2000) EMBO J. 
19:5194-5201). 
In some instances, the polynucleotide encodes an antibody 
that binds to at least one cytochrome P450 polypeptide, and 
reduces the activity of a cytochrome P450 polypeptide of the 
present invention. In another embodiment, the binding of the 
antibody results in increased turnover of the antibody-cyto-
chrome P450 polypeptide complex by cellular quality control 
mechanisms. The expression of antibodies in plant parts and 
the inhibition of molecular pathways by expression and bind-
ing of antibodies to proteins in plant parts are well known in 
the art. See, e.g., Conrad & Sonnewald (2003) Nature Bio-
tech. 21:35-36, incorporated herein by reference as if set forth 
in its entirety. 
The activity of a cytochrome P450 polypeptide of the 
present invention can be reduced or eliminated by disrupting 
the gene encoding the cytochrome P450 polypeptide. 
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The gene encoding the cytochrome P450 polypeptide may 
be disrupted by any method known in the art, e.g., by trans-
poson tagging or by mutagenizing plants using random or 
targeted mutagenesis and selecting for plants that have 
reduced nicotine demethylase activity or mutations in 5 
CYP82E4v2 or CYP82E5v2. 
30 
ing sequences and not other P450 sequences may be benefi-
cial to the recombinant plant. That is, strategies that would 
lead to inhibition of gene function of this individual locus 
Transposon tagging may be used to reduce or eliminate the 
activity of one or more cytochrome P450 polypeptides of the 
present invention. Transposon tagging comprises inserting a 
transposon within an endogenous cytochrome P450 gene to 
reduce or eliminate expression of the cytochrome P450 
polypeptide. 
Methods for the transposon tagging of specific genes in 
plants are well known in the art. See, e.g., Maes eta!. (1999) 
Trends Plant Sci. 4:90-96; Dharmapuri & Santi (1999)FEMS 
Micerobiol. Lett. 179:53-59; Meissner eta!. (2000) Plant J. 
22:265-274; Phogat eta!. (2000) J. Biosci. 25:57-63; Walbot 
(2000) Curr. Opin. Plant Biol. 2:103-107; Gai eta!. (2000) 
Nucleic Acids Res. 28:94-96; and Fitzmaurice eta!. (1999) 
Genetics 153: 1919-1928). 
may prove to be superior to those that inhibit the entire gene 
family. The P450 enzymes are involved in many mechanisms 
in the plant, the inhibition of which may prove deleterious or 
detrimental to the growth and development of the plant or 
may negatively impact factors such as the disease defense 
capabilities of the plant. Likewise, because the Nicotiana 
10 plant P450 enzymes have been implicated in plant metabo-
lites such as phenylpropanoid, alkaloids, terpenoids, lipids, 
cyanogenic glycosides, glucosinolates, and a host of other 
chemical entities, disruption ofP450 activity may alter com-
15 ponents involved in tobacco flavor, texture, or other proper-
ties that would impact the commercial usefulness of the plant. 
Therefore, the use of the methods discussed above to inhibit 
expression in a manner that specifically targets the sequence 
coding for SEQ ID N0:2 or 13 may be preferred, including 
Additional methods for decreasing or eliminating the 
expression of endogenous genes in plants are also known in 
the art and can be similarly applied to the instant invention. 
These methods include other forms of mutagenesis, using 
mutagenic or carcinogenic compounds including ethyl meth-
anesulfonate-induced mutagenesis, deletion mutagenesis, 
and fast neutron deletion mutagenesis used in a reverse genet-
20 targeted mutational strategies, such as chimeraplasty. See, 
e.g., Stewart et a!. (2000) Biotechniques 24:838-843; and 
Graham eta!. (2002) Biochim Biophys Acta 1587: 1-6; each of 
which is incorporated herein by reference as if set forth in its 
entirety. In some embodiments, the methods discussed above 
25 are used to inhibit expression in a manner that specifically 
targets SEQ ID N0:1 (encoding SEQ ID N0:2), SEQ ID 
N0:50 (encoding SEQ ID N0:13), or both of these 
sequences. ics sense (with PCR) to identify plant lines in which the 
endogenous gene has been deleted. For examples of these 
methods see, Ohshima eta!. (1998) Virology 213:472-481; 30 
Okubara eta!. (1994) Genetics 137:867-874; and Quesada et 
The compositions of the invention can be used in screening 
methods to identifY nonconverter plants for use in breeding 
programs. In this manner, the nucleotide sequences of the 
invention can be used to screen native germplasms for non-
converter plants having a stable mutation in one or more P450 
genes identified herein. These nonconverter plants identified 
by the methods of the invention can be used to develop breed-
ing lines. 
In addition to the nucleotide sequences encoding P450 
coding sequences, compositions of the invention include an 
intron sequence in the CYP82E5v2 sequence that can be used 
a!. (2000) Genetics 154:421-4315; each of which is incorpo-
rated herein by reference as if set forth in its entirety. In 
addition, a fast and automatable method for screening for 
chemically induced mutations, TILLING (Targeting Induced 35 
Local Lesions In Genomes ), using denaturing HPLC or selec-
tive endonuclease digestion of selected PCR products is also 
applicable to the instant invention. See, McCallum et a!. 
(2000) Nat. Biotechnol. 18:455-457, herein incorporated by 
reference. 
Mutations that impact gene expression or that interfere 
with the function of the encoded cytochrome P450 protein 
can be determined using methods that are well known in the 
art. Insertional mutations in gene exons usually result in null-
mutants. Mutations in conserved residues can be particularly 45 
effective in inhibiting the metabolic function of the encoded 
protein. Conserved residues of plant cytochrome P450 
polypeptides suitable for mutagenesis with the goal to elimi-
nate activity of a cytochrome P450 polypeptide in converting 
nicotine to nornicotine in a Nicotiana plant or plant part have 50 
been described. Conserved residues of plant cytochrome 
P450 polypeptides are disclosed in FIG. lA-C, where the 
residues that differ from the other P450 polypeptides are 
shaded in grey. The conserved residue is that which is not 
shaded in grey at each position. Such mutants can be isolated 55 
according to well-known procedures. 
40 in screening methods. While not intending to be bound by any 
particular mechanism of action, the CYP82E5v2 gene( s) may 
represent the only member( s) of the cytochrome P450 family 
involved in the metabolic conversion of nicotine to nornico-
Dominant mutants can be used to trigger RNA silencing 
due to gene inversion and recombination of a duplicated gene 
locus. See, e.g., Kusaba et a!. (2003) Plant Cell 15:1455-
1467. 
While a number of sequences are recognized in the practice 
of the invention, in particular sequences encoding SEQ ID 
N0:2 and 13 find particular use. While not intending to be 
bound by any particular mechanism of action, the inventors 
believed that these sequences encode a nicotine demethylase 
that catalyzes the oxidative N-demethylation of nicotine to 
nornicotine. Thus, methods to specifically inhibit these cod-
tine (and as stated previously there is a good likelihood that 
the CYP82E5v2 cDNAs originated from a single unique 
genetic locus) in green-leaves of tobacco. For certain appli-
cations, it would be useful to have a means of diagnostically 
differentiating this specific member of the cytochrome P450 
gene family from the rest of the closely related sequences 
within this family. For example, it is possible that within the 
naturally existing tobacco germplasm (or in mutagenized 
populations), accessions may exist in which this gene is natu-
rally dysfunctional and may therefore may be valuable as a 
permanently nonconverter resource. Such dysfunctional 
genes may include those encoding the polypeptides set forth 
in SEQ ID NOS:6 and 12. A method to specifically assay for 
such genotypes (e.g., deletion mutants, rearrangements, and 
the like) could serve as a powerful tool. The present invention 
includes primers designed to specifically amplifY exon 1 and 
60 ex on 2 of CYP82E5v2 or CYP82E4v2 where one of the two 
primer pairs corresponds to the intron between the exons. 
Examples of primers useful to amplifY the exons of 
CYP82E4v2 include SEQ ID N0:32 with SEQ ID NOS:33-
35. Examples of primers useful to amplifY the exons of 
65 CYP82E5v2 include SEQ ID N0:36 with 37 and SEQ ID 
N0:38 with 39. These same primers can be used for sequence 
analysis of the products. 
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When any eDNA corresponding to a member of the 
CYP82E2 family is used as a hybridization probe in a South-
em blotting assay of tobacco genome is DNA, a complex 
pattern is observed. This is expected, given that there are 
multiple, closely related members of this gene family. 5 
Because the intron regions of genes are typically less con-
served than exons, it is predicted that the use of an intron-
specific probe would reduce this complexity and better enable 
one to distinguish the gene(s) corresponding to the 
CYP82E4v2 gene or the CYP82E5v2 gene from the other 10 
members of the family. The use of a CYP82E4v2 or 
CYP82E5v2 intron-specific probe, and/or the PCR primers 
used to generate products provide powerful tools in assays to 
determine whether any naturally occurring, or mutagenized, 
tobacco plants possess deletions or rearrangements that may 15 
render the gene inactive. Such a plant can then be used in 
breeding programs to create tobacco lines that are incapable 
of converting. 
32 
(1992) Plant Cell 4:1495-1505 (electroporation); each of 
which is incorporated herein by reference as if set forth in its 
entirety. 
Any plant tissue that can be subsequently propagated using 
clonal methods whether by organogenesis or embryogenesis, 
may be transformed with a recombinant construct comprising 
a cytochrome P450 inhibitory sequence, for example, an 
expression cassette of the present invention. As used herein, 
"organogenesis" means a process by which shoots and roots 
are developed sequentially from meristematic centers. As 
used herein, "embryogenesis" means a process by which 
shoots and roots develop together in a concerted fashion (not 
sequentially), whether from somatic cells or gametes. Exem-
plary tissues that are suitable for various transformation pro-
tocols described herein include, but are not limited to, callus 
tissue, existing meristematic tissue (e.g., apical meristems, 
axillary buds and root ineristems) and induced meristem tis-
sue (e.g., cotyledon meristem and hypocotyl meristem), 
hypocotyls, cotyledons, leaf disks, pollen, embryos and the Transformed Plants, Plant Parts and Products Having 
Reduced Nornicotine and NNN Content 20 like. 
The cytochrome P450 polynucleotides of the invention, 
and variants and fragments thereof, can be used in the meth-
ods of the present invention to inhibit cvtochrome P450s that 
are involved in the metabolic conversion of nicotine to nor-
nicotine in a plant. In this marmer, inhibitory sequences that 25 
target expression or function of a cytochrome P450 polypep-
tide disclosed herein are introduced into a plant or plant cell of 
interest. The expression cassettes described herein can be 
introduced into a plant of interest, for example, a Nicotiana 
plant as noted herein below, using any suitable transformation 30 
methods known in the art including those described herein. 
The methods of the invention do not depend on a particular 
method for introducing a sequence into a plant or plant part, 
only that the desired sequence gains access to the interior of at 
least one cell of the plant or plant part. Methods for introduc- 35 
ing polynucleotide sequences into plants are known in the art 
and include, but are not limited to, stable transformation 
methods, transient transformation methods and viral-medi-
ated transformation methods. 
As used herein, "stable transformation" means that the 
nucleotide construct of interest introduced into a plant inte-
grates into the genome of the plant and is capable of being 
inherited by the progeny thereof. Likewise, "transient trans-
formation" means that a sequence is introduced into the plant 
and is only temporally expressed or is only transiently present 
in the plant. 
The inhibitory sequences of the invention can be provided 
to a plant using a variety of transient transformation methods. 
The inhibitory sequences of the invention can be transiently 
transformed into the plant using techniques known in the art. 
Such techniques include viral vector systems and the precipi-
tation of the polynucleotide in a marmer that precludes sub-
sequent release of the DNA. Thus, the transcription from the 
particle-bound DNA can occur, but the frequency with which 
it is released to become integrated into the genome is greatly 
reduced. Such methods include the use of particles coated 
with polyethyenlimine (PEl; Sigma 4P3143). 
Alternatively, the inhibitory sequence of the invention may 
Transformation protocols as well as protocols for introduc-
ing heterologous polynucleotide sequences into plants vary 
depending on the type of plant or plant cell targeted for 
transformation. Suitable methods of introducing polynucle-
otides into plant cells of the present invention include micro-
injection (Crossway eta!. (1986) Biotechniques 4:320-334), 
electroporation (Shillito eta!. (1987) Meth. Enzymol. 153: 
313-336; and Riggs eta!. (1986) Proc. Nat!. Acad. Sci. USA 
83:5602-56116), Agrobacterium-mediated transformation 
(U.S. Pat. Nos. 5,104,310; 5,149,645; 5,177,010; 5,231,019; 
5,463,174; 5,464,763; 5,469,976; 4,762,785; 5,004,863; 
5,159,135; 5,563,055 and 5,981,840), direct gene transfer 
(Paszkowski eta!. (1984) EMBO J. 1 :2717-2722) and ballis-
40 be introduced into plants by contacting plants with a virus or 
viral nucleic acids. Generally, such methods involve incorpo-
rating an expression cassette of the invention within a viral 
DNA or RNA molecule. Promoters for use in the expression 
cassettes of the invention also encompass promoters utilized 
45 for transcription by viral RNA polymerases. Methods for 
introducing polynucleotides into plants and expressing a pro-
tein encoded therein, involving viral DNA or RNA mol-
ecules, are known in the art. See, e.g., U.S. Pat. Nos. 5,889, 
191; 5,889,190; 5,866,785; 5,589,367; 5,316,931; and Porta 
50 eta!. (1996) Molecular Biotechnology 5:209-221; each of 
which is incorporated herein by reference as if set forth in its 
entirety. 
Transformed cells may be grown into Nicotiana plants in 
accordance with conventional methods. See, e.g., Vasil & 
55 Hildebrandt (1965) Science 150:889; Negaard & Hoffman 
(1989) Biotechniques 7(8):808-812. These plants may then 
be grown, and either pollinated with the same transformed 
line or different lines, and the resulting progeny having 
expression of the desired phenotypic characteristic identified, 
tic particle acceleration (U.S. Pat. Nos. 4,945,050; 5,141,131; 
5,886,244; 5,879,918 and 5,932,782; Tomes eta!. (1995) in 
Plant cell, tissue, and organ culture fundamental methods, ed. 
Gamborg & Phillips (Springer-Verlag, Berlin); McCabe eta!. 
(1988) Biotechnology 6:923-926). See also, Weissinger eta!. 
(1988) Ann. Rev. Genet. 22:421-477; Christon eta!. (1988) 
Plant Physiol. 87:671-674 (soybean); McCabe eta!. (1988) 
Bio/Technology 6:923-926 (soybean); Finer & McMullen 
(1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh 
eta!. (1998) Theor. Appl. Genet. 96:319-324 (soybean); De 
Wet et a!. (1985) in The experimental manipulation of ovule 
tissues, ed. Chapman eta!. (Longman, New York.); pp. 197-
209 (pollen); Kaeppleret a!. (1990)Plant Cell Reports 9:415- 65 
418; and Kaeppler eta!. (1992) Theor. Appl. Genet, 84:560-
566 (whisker-mediated transformation); D'Halluin et a!. 
60 i.e., reduced expression of one or more nicotine demethylases 
that are involved in the metabolic conversion of nicotine to 
nornicotine, and thus reduced content of nornicotine, and a 
concomitant reduced content of its nitrosamine metabolite, 
NNN, in the plant, particularly in the leaf tissues. Two or more 
generations may be grown to ensure that expression of the 
desired phenotypic characteristic is stably maintained and 
inherited and then seeds harvested to ensure expression of the 
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desired phenotypic characteristic has been achieved. In this 
manner, the present invention provides transformed seed 
(also referred to as "transgenic seed") having a polynucle-
otide of the invention, for example, an expression cassette of 
the invention, stably incorporated into their genome. 
The compositions and methods of the invention can be 
used to reduce the nomicotine content, particularly in the 
leaves and stems, of any plant of the genus Nicotiana includ-
ing, but not limited to, the following species: acuminata, 
ajfinis, alata, attenuate, bigelovii, clevelandii, excelsior,for- 10 
getiana, glauca, glutinosa, langsdorjfii, longiflora, obtusifo-
lia, palmeri, paniculata, plumbaginifolia, qudrivalvis, 
repanda, rustica, suaveolens, sylvestris, tabacum, tomentosa, 
trigonophylla and x sanderae. The present invention also 
15 
encompasses the transformation of any varieties of a plant of 
the genus Nicotiana, including, but not limited to, Nicotiana 
acuminata multiflora, Nicotiana alata grandiflora, Nicotiana 
bigelovii quadrivalvis, Nicotiana bigelovii wallacei, Nicoti-
ana obtusifolia obtusifolia, Nicotiana obtusifolia plameri, 20 
Nicotiana quadrivalvis bigelovii, Nicotiana quadrivalvis 
quadrivalvis, Nicotiana quadrivalvis wallacei, andNicotiana 
trigonophylla palmeri, as well as varieties commonly known 
as flue or bright varieties, Burley varieties, dark varieties and 
oriental/Turkish varieties. 25 
The transgenic plants of the genus Nicotiana as described 
herein are suitable for conventional growing and harvesting 
techniques, such as cultivation in manure rich soil or without 
manure, bagging the flowers or no bagging, or topping or no 
topping. The harvested leaves and stems may be used in any 30 
traditional tobacco product including, but not limited to, pipe, 
cigar and cigarette tobacco, and chewing tobacco in any form 
including leaf tobacco, shredded tobacco, or cut tobacco. 
Thus the present invention provides a Nicotiana plant, 
particularly leaf tissues of these plants, comprising an expres- 35 
sian cassette of the invention and a reduced amount of norni-
34 
The tobacco products described herein reduce the carcino-
genic potential of tobacco smoke that is inhaled directly with 
consumption of a tobacco product such as cigars, cigarettes, 
or pipe tobacco or inhaled as secondary smoke (i.e., by an 
individual that inhales the tobacco smoke generated by an 
individual consuming a tobacco product such as cigars, ciga-
rettes, or pipe tobacco). The cured tobacco described herein 
can be used to prepare a tobacco product, particularly one that 
undergoes chemical changes due to heat, comprising a 
reduced amount of nornicotine and/or NNN in the smoke 
stream that is inhaled directly or inhaled as secondary smoke. 
In the same manner, the tobacco products of the invention 
may be useful in the preparation of smokeless tobacco prod-
ucts such as chewing tobacco, snuff and the like. 
The tobacco products derived from the transgenic tobacco 
plants of the present invention thus find use in methods for 
reducing the carcinogenic potential of these tobacco prod-
ucts, and reducing the exposure of humans to the carcino-
genic nitrosamine, NNN, particularly for individuals that are 
users of these tobacco products. The following examples are 
offered by way of illustration and not by way of limitation. 
EXPERIMENTAL 
The following materials and protocols are utilized in the 
experiments described herein below. 
Plant Materials 
All plant materials were obtained from Dr. Earl Wemsman, 
Department of Crop Science, North Carolina State University 
(Raleigh, N.C.). N. tomentosiformis and N. sylvestris seed 
were obtained from the Nicotiana germplasm collection 
maintained by North Carolina State University. Plants were 
grown in growth chambers for two months until they were 
transferred to a greenhouse. Burley lines DH 98-325-5 (non-
converter) and DH 98-325-6 (converter) represent near-
isogenic lines, i.e., recovered from the same maternal haploid 
plant. SC58 is a flue-cured tobacco variety, nonconverter 
individuals of which are designated SC58(czer)· SC58 
(CrCr) is a near-isogenic stable converter line that originated 
cotine and N'-nitrosonornicotine. As used herein, "a reduced 
amount" or "a reduced level" means an amount of nornicotine 
and/or NNN in a treated or transgenic plant of the genus 
Nicotiana or a plant part or tobacco product thereof that is less 
than what would be found in a plant of the genus Nicotiana or 
40 though the introgression of the single dominant converter 
locus (Cr) found in the tobacco progenitor species N. tomen-
tosiformis into SC58 (Mann eta!. (1964) Crop Sci., 4:349-
353). After eight additional backcrosses to SC58, the near-
isogenic SC58(CrCr) line was created and was subsequently 
a plant part or tobacco product from the same variety of 
tobacco, processed (i.e., cultured and harvested) in the same 
manner, that has not been treated or was not made transgenic 
for reduced nornicotine and/or NNN. The amount of norni-
cotine may be reduced by about 10% to greater than about 
90%, including greater than about 20%, about 30%, about 
40%, about 50%, about 60%, about 70% and about 80%. The 
conversion of nicotine to nornicotine can be less than 0.3%, 
less than 0.5%, less than 0.7%, between 0.1 %-0.5%, between 50 
0.1 %-0.4%, between 0.1 %-0.7%, or between 0.1%-1.0% in 
plants, plant parts, and products of the present invention, and 
more specifically in plants, plant parts having mutations in 
CYP82E4v2 and CYP825v2. 
45 maintained via self-fertilization. 
As used herein, "tobacco products" means, but is not lim- 55 
ited to, smoking materials (e.g., any cigarette, including a 
cigarillo, a non-ventilated or vented recess filter cigarette, a 
cigar, pipe tobacco), smokeless products (e.g., snuff, chewing 
tobacco, biodegradable inserts (e.g., gum, lozenges, dissolv-
ing strips)). See, e.g., US Patent Application Publication No. 60 
2005/0019448, incorporated herein by reference as if set forth 
in its entirety. Tobacco product also includes blends that can 
be made by combining conventional tobacco with differing 
amounts of the low nomicotine and/or NNN tobacco 
described herein. Tobacco products also includes plant or 65 
plant part of the genus Nicotiana as described above is cured 
tobacco. 
All plants were maintained in growth chambers or green-
houses using standard potting soil and fertilizer. Plants kept in 
a 14/10 light/dark cycle, were watered once a day as needed 
and fertilized with Peters Professional® All Purpose Plant 
Food fertilizer (20-20-20; Spectrum Brands Inc.; Madison, 
Wis.) once a week. To facilitate senescence, detached green 
leaves were treated by dipping each leaf for 30 seconds in a 
0.2% ethephon solution. Leaves were cured in plastic bags 
under dark conditions until they turned yellow. 
For the ethyl methane sulphonate (EMS) mutagensis, two 
grams of seed from the strong converter Burley tobacco line 
DH98-325-6 were surface-sterilized in 50% bleach for 12 
minutes and rinsed 6 times in sterile dH2 0. Approximately 80 
mg aliquots were then placed in screw cap vials and imbibed 
in 1 ml dH2 0 for 12 hours. The dH20 was decanted, and the 
seed was incubated in 1 ml of0.5% EMS (Sigma; St. Louis, 
Mo.) and rocked gently on a Nutator® Mixer (TCS Scientific 
Corp.; New Hope, Pa.) at room temperature for 12 hours in 
the dark. After removal of the EMS solution, the treated seeds 
were washed eight times in 1 ml volumes of dH2 0 with gentle 
shaking for 5 minutes. After the final wash, seeds were col-
lected onto a Buchner funnel for a final rinse and subse-
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quently allowed to dry on filter paper before sowing on soil. 
Seedlings were grown on standard float trays for about 7 
weeks, then transplanted to a field. Field-grown plants were 
allowed to self-pollinate, and 5-10 capsules (containing M1 
generation seed) per plant were collected and catalogued 5 
corresponding to approximately 4000 independent M0 indi-
viduals. 
Isolation ofNtabCYP82E5v2 eDNA 
36 
vector (Cullin & Pompon 1988). The recombinant plasmid 
was introduced into WAT11 yeast strain using the lithium-
acetate-based transformation method as described by Gietz et 
a!. (1992) Nucleic Acids Res. 20:1425-1425. Yeast culturing, 
galactose-mediated induction of gene expression and the iso-
lation of the microsomal fractions were performed according 
to the protocol of Pompon eta!. (1996) Methods Enzymol. 
2n:51-64. 
Total RNA was extracted from green and senescing leaves 
10 
Kinetic Analysis of NtabCYP82E5-Mediated Nicotine 
of DH98-325-6 tobacco using TRizol® (Invitrogen; Carls- Metabolism 
The nicotine metabolism assays were performed in a reac-
tion mixture containing 0.75 mM NADPH, 2.5 f.LM [pyrroli-
dine-2-14C] nicotine (Moravek Biochemicals; Brea, Calif.) 
15 and 90 flg of yeast microsomes in a final volume of 150 fll Pi 
buffer, pH 7 .1. Nicotine concentrations were adjusted by the 
addition of nonradiolabelled nicotine to final concentrations 
bad, Calif.) following the protocol of the manufacturer. 
Genomic DNA was removed by treating the extracts with 
TURBO DNA-free™ DNase Kit (Ambion; Austin, Tex.) fol-
lowing the protocol of the manufacturer. eDNA synthesis was 
performed with the StrataScript™ First-Strand Kit (Strat-
agene; Cedar Creek, Tex.) using oligo dT primers and 3 flg of 
DNase-free total RNA. Full-length NtabCYP82E5v2 cDNAs 
were amplified using the ESOrf_F forward and E50rf_R 20 
ranging between 0.7 and 13 f.LM. Microsomal preparations 
isolated from yeast containing an empty vector were used as 
negative control. Reaction mixtures were incubated at 25° C. 
for 7 minutes, and the reaction was arrested with 50 fll of 
acetone. After centrifugation at 16,000xg for 3 minutes, 50 fll 
the sample was spotted on a 250-f.tm Whatman K6F silica 
reverse primers, 10 ng tobacco leaf eDNA library as a tem-
plate and Long Range™ PCR Enzyme Blend (GeneChoice, 
Inc.; Frederick, Md.) following the protocol of the manufac-
turer. DNA sequence information of the primers is listed in 
the sequence listing and above. PCR conditions were as fol-
lows: 3 minutes initial denaturation at 95° C. followed by 33 
cycles of denaturation at 94° C. for 30 seconds, annealing at 
60° C., for 30 seconds and extension at 68° C. for 90 seconds, 
followed by an incubation at 68° C. for 7 minutes. PCR 
30 
products were cloned into pGEM®-T Easy cloning vector 
(Prom ega Corp.; Madison, Wis.) and sequenced according to 
the dideoxy method using synthetic oligonucleotides as prim-
25 plate. The plates were developed in choloroform:methanol: 
ammonia ( 60:10:1) solvent system. Nicotine and its nomico-
tine derivative were quantified by measuring the relative 
abundance of their radioactive traces with a Bioscan System 
400 imaging scanner. Km and v max values were calculated by 
fitting the Michaelis-Menten equation to nicotine demethy-
lation measurements at different substrate concentrations 
using the SigmaPlot® 10.0 graphing software (Systat Soft-
ware, Inc.; San Jose, Calif.). ers (Sanger et a!. (1977) Proc. Nat!. Acad. Sci. U.S.A. 74: 
5463-5467). 
Isolation of the Genomic CYP82E5 Fragments 
35 Quantitative Real-Time PCR Analysis of CYP82E4v2 and 
CYP82E5v2 Expression 
Genomic DNA was isolated from the green leaves of N. 
tomentosiformis and DH98-325-6 tobacco using a cetyltrim-
ethyl ammonium bromide-based extraction procedure 
40 
according to the instructions of the NucleoSpin® Plant kit 
(BD Bioscience Clontech; Palo Alto, Calif.). 
Expression of the N. tomentosiformis and tobacco 
orthologs ofCYP82E4v2 and CYP82E5v2 were analyzed by 
allele-specific, quantitative real-time PCR ( qrt-PCR) analysis 
using SYBR® Green I fluorescence chemistry (Morrison et 
a!. (1998) Biotechniques 24: 954-962). Total RNA was 
extracted from the green and cured leaves of 3-month-old 
plants using the methods already described for 
Genomic fragments of the CYP82E5 orthologs were 
amplified in two consecutive PCR reactions using nested 
primers. The first PCR mixture contained 0.5 f.LM each of the 
E5Gen_F1 forward (SEQ ID N0:40) and E5Gen R1 reverse 
(SEQ ID N0:41) primers, 200 f.LM of each dNTP, 20 ng of 
genomic DNA template and 2 U of Platinum® Taq poly-
merase (Invitrogen). PCR amplification was performed under 
45 NtabCYP82E5v2 eDNA isolation herein. CYP82E4v2 and 
50 
the following conditions: 90° C. for 3 minutes; 30 cycles of 
denaturation at 94 o C. for 30 seconds, annealing at 57° C. for 
30 seconds and extension at 68° C. for 2.2 minutes followed 
by a final extension at 68° C. for 5 minutes. The composition 
and conditions of the second PCR were the same as those 55 
described for the first amplification, except primers 
E5Gen_F2 (SEQ ID N0:42) and E5Gen_R2 (SEQ ID 
N0:43) were added and 1 fll of a 50-fold diluted sample of the 
first PCR product was used as a template. The purified prod-
ucts of the final PCR were ligated into the pGEM-T-Easy 60 
cloning vector and subjected to DNA sequencing. 
Expression of the NtabCYP82E5v2 eDNA in Yeast 
CYP82E5v2 transcripts were amplified using the E4Rt_F 
(SEQ ID N0:44) and E5Rt_F (SEQ ID N0:46) forward in 
conjunction with the E4Rt_R (SEQ ID N0:45) and the 
E5Rt_R reverse (SEQ ID N0:47) primers, respectively. The 
qrt-PCRmixture contained 1 xiQ™ SYBR® Green Supermix 
(Bio-Rad Laboratories) 0.5 f.LM of each primer and 0.5 flg of 
eDNA. Transcript measurements were obtained using stan-
dard curves generated by amplifying known amounts of tar-
get DNA and a 220-bp fragment of the glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) gene, amplified with the 
G3PDH_F (SEQ ID N0:48) and G3PDH_R (SEQ ID N0:49) 
primers, to provide an internal standard for eDNA measure-
ments. DNA amplifications were performed using the real 
time PCR system (Bio-Rad Laboratories; Hercules, Calif.) 
under the following conditions: 95° C. for 2 minutes; 35 
cycles of 95° C. for 30 seconds, 57 C for 30 seconds, no C. 
for 50 seconds followed by final extension at no C. for 5 To facilitate the expression of the NtabCYP82E5v2 eDNA 
in yeast, the open reading frame of the gene was inserted 
downstream of the galactose-inducible, glucose-repressed 
GAL10-CYC1 promoter of the pYeDP60 yeast expression 
65 minutes. DNA sequences of the amplicons generated by qrt-
PCR were verified by cloning the PCR products and sequenc-
ing 20 randomly selected clones. 
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Transgenic Plant Analysis 
The RNAi-based gene silencing constructs are assembled 
in a version of the pKYL80 cloning vector (Schardl et a!. 
(1987) Gene 61:1-11) that is engineered to contain a 151-bp 
fragment of the soybean FAD3 gene intron between the Xhol 
and Sac! restriction sites of the polylinker (pKYLX80I). To 
create a construct in which the FAD3 intron was flanked by a 
sense and antisense fragment ofCYP82E5v2, a 400-bp intron 
region is cloned between the Hindiii-Xhol and Sacl-Xbal 
restriction sites of pKYLX801 in its sense and antisense 
orientation, respectively. The resulting Hindiii-Xbal frag-
ment containing the CYP8E5v2 sense arm, FAD3 intron, and 
CYP82E5v2 antisense arm is subcloned into the pKYLX71 
plant binary expression vector (Maiti eta!. (1993) Proc. Nat!. 
Acad. Sci. USA 90:6110-6114) between the 35S CaMV pro-
moter and a rubisco small subunit terminator. 
Overexpression constructs are created by replacing the 
3-glucuronidase ORF of the plant binary expression vector 
pBI121 (Clontech) with the full-length coding regions of the 
CYP82E5v2, CYP82E5v2 variants, or CYP82E4v2 variants 
38 
Template Preparation for Sequencing. 
CYP82E4v2 and CYP82E5v2 each contain two exons 
separated by a large intron (1001 bp and 1054 bp, respec-
tively). PCR primers are designed to specifically amplify 
5 exon 1 and exon 2 for each gene. Due to the high sequence 
homology shared among the cDNAs of CYP82E2 gene fam-
ily members, two primer pairs correspond to intron sequence 
in order to obtain amplification products specific to the 
desired gene (owing to the fact that the intron sequences of 
10 this gene family are not nearly as conserved as the exon 
sequences). The exon !-specific primers for CYP82E4v2 are 
5'-TGGAATTATGCCCATCCTACA-3' (forward) (SEQ ID 
N0:32) and 5'-CATTAGTGGTTGCACCTGAGG-3' (re-
15 verse) (SEQ ID N0:33). CYP82E4v2 exon 2-specific primers 
are 5'-GATGAGATGTGTGCATACTTG-3' (forward) (SEQ 
ID NO: 34) and 5'-CCAAATTAGAAAAACTCGTACTG-3' 
(reverse) (SEQ ID N0:35). For CYP82E5v2, the primers 
specific for amplifying exon 1 are 5'-ATTGTAGGACTAG-
20 
cDNAs. This places the tobacco P450s under the transcrip-
tional control of the 35S CaMV promoter. The pBI121- and 25 
TAACCCTTACAC-3' (forward) (SEQ ID N0:36) and 
5'-GAGGCACAAAGAATTCTCATC-3' (reverse) (SEQ ID 
N0:37); and for CYP82E5v2 exon 2, the primers 5'-GAG-
TAGAGGGATTGTTTCCG-3' (forward) (SEQ ID N0:38) 
and 5'-GTACAATCAAGATAAAACATCTAAGG-3' (re-
verse) (SEQ ID N0:39) are used. PCR reactions were con-
ducted in 96-well microtiter plates using 1 fll of template in a 
25 fll reaction volume containing 10 pmoles each primer, 200 
f.LM dNTP, 1.5 mM MgCl and 1.4 units of high fidelity Tag 
pKYLX71-based constructs are transformed into Agrobacte-
rium tumefaciens strain LBA 4404 and introduced into 
tobacco cultivars Petite Havana and DH98-325-6 (converter), 
respectively, using established protocols (Horsch eta!. (1985) 
Science 227:1229-1231). 
Northern Blot Analysis 
Total cellular RNAs are isolated from tobacco leaves using 
the TRIZOL® method as described by the manufacturer (In-
vitrogen). Five to ten micrograms of RNA are size fraction-
ated on a 1.2% agarose gel prepared in TBE buffer. RNA 
immobilization, probe labeling, and signal detection are car-
ried out using the DIG nucleic acid labeling and detection kits 
according to the manufacturer's instructions (Roche). Alter-
natively, probes are synthesized using 32P-dCTP according to 
protocols accompanying the Random Primed DNA Labeling 
30 
DNA polymerase (Roche). DNA amplification of 
CYP82E4 v2 sequences was performed using an initial3 min-
utes denaturation at 94° C., followed by 30 cycles of dena-
turation at 94 o C. for 30 seconds, primer annealing at 55° C. 
for 30 seconds, and extension at 72° C. for 1.5 minutes, 
35 followed by a final 7 minutes 72o C. extension. Amplification 
conditions for CYP82E5v2 gene fragments were the same 
except the annealing temperature was 53° C. PCR reaction 
products were purified using Millipore's Montage PCRf196 
40 
filter units. Agarose gel electrophoresis was used to estimate 
the quantity and quality of the cleaned up PCR products prior 
kit (Roche). 
Isolation of DNA from EMS-Mutagenized Plants. 
Genomic DNA was isolated from young leaf material of a 45 
single greenhouse-grown M1 plant from each independent 
M1 seed pool. 1.5 ml screw cap vials were used to collect a 
single leaf disc from each plant and the samples were stored 
at -80° C. until they were processed. The leaf tissue was 
50 
deposited to the bottom of the vial by centrifugation, and the 
tubes were set in a shallow amount of liquid nitrogen to 
facilitate grinding using plastic pestles. Genomic DNA was 
isolated from the ground material by adding 320 fll extraction 
buffer (200 mM Tris-Cl, pH 7.5, 250 mM NaCl, 25 mM 55 
EDTA, 0.5% SDS). Samples were vortexed for 20 seconds, 
and left at room temperature for 5 minutes, followed by a 3 7° 
C. incubation for 3 minutes. The lysed material was centri-
fuged 10 minutes, and the supernatant transferred to fresh 
tube. 50 fll of protein precipitation solution (Qiagen) was 60 
added, the samples briefly vortexed, then set on ice for 5 
minutes, followed by a 4 minutes centrifugation at 16,000xg. 
Precipitation of nucleic acids was accomplished by adding 
0.7 volume isopropanol to the supernatant followed by cen- 65 
trifugation for 7 minutes at 12,000xg. After a 70% ethanol 
wash, the pellet was resuspended in 50 fll TE. 
to sequencing. 
Sequence Analysis. 
The PCR products were subjected to cycle sequencing 
using Applied Biosystems Big Dye Version 3.1 in 96-well 
format sequencing reactions according to the manufacturer's 
instructions. The primers used for sequencing (3 .2 pmoles per 
reaction) are as follows: 5'-TGGAATTATGCCCATC-
CTACA-3' (SEQ ID N0:32) and 5'-CCTATAAAAAG-
GAAGTTGCCG-3' (SEQ ID N0:44) (forward and reverse 
primers for exon 1 of CYP82E4v2); 5'-GATGAGATGTGT-
GCATACTTG-3' (SEQ ID N0:34) and 5'-CCAAATTA-
GAAAAACTCGTACTG-3' (SEQ ID N0:35) (forward and 
reverse primers for exon 2 of CYP82E4v2); 5'-ATTGTAG-
GACTAGTAACCCTTACAC-3' (SEQ ID N0:36) and 5'-CT-
CATCTTTTTTCCATTTATCATTC-3' (SEQ ID N0:45) 
(forwardandreverseprimers forexon 1 ofCYP82E5v2); and 
5'-CAAGGTTCGGCAGATAGTG-3' (SEQ ID N0:46) and 
5'-GTACAATCAAGATAAAACATCTAAGG-3' (SEQ ID 
N0:39) (forward and reverse primers for exon 2 of 
CYP82E5v2). Sequencing reactions were cleaned up using 
EdgeBioSystems 96-well plates and analyzed using high-
throughput Applied Biosystems 3700 or 3730 capillary 
sequencers. Sequences were aligned using the Clustal W 
algorithm as represented in the Vector NTI software package 
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(Invitrogen). Putative mutations are verified by repeating the 
sequence analysis on sibling M1 plants grown from the cog-
nate M0 seed lot. 
Alkaloid Analysis 
Alkaloid analyses are performed by gas chromatography 
as described previously. Briefly, alkaloid analyses are per-
formed by detaching tobacco leaves and dipping them in a 
solution of 1% ethephon, then, air-curing in a growth cham-
ber for 7-10 days. Cured leaves are dried at 50° C. for two 10 
days and ground to a fine powder. A quantitative determina-
tion of the nicotine, nomicotine, anatabine and anabasine 
content was made using a Perkin Elmer Auto system XL Gas 
Chromatograph according to the "LC-Protocol" established 
at the University of Kentucky (available online at the Univer- 15 
sity of Kentucky's website), hereby incorporated by refer-
ence. 
EXAMPLE 1 
40 
where the primers are complementary to the 5' and 3' termini 
of the NtabCYP82E3 coding region. Primer design was based 
on the observation that all members of the closely-related 
CYP82E2 gene subfamily display a high degree of DNA 
sequence identity at the regions immediately following the 
ATG initiation signal and preceding the TAA stop codon 
(Siminszky eta!. (2005) Proc. Nat!. Acad. Sci. U.S. A. 102: 
14919-14924) providing well conserved primer target sites 
for the amplification of additional family members. A PCR 
using CYP82E3-specific primers and permissive annealing 
temperatures was conducted to amplify putative nicotine 
demethylase genes from a tobacco green leaf eDNA library. 
DNA sequence analysis of 20 randomly selected clones gen-
erated from the PCR products yielded 19 NtabCYP82E3 
eDNA sequences and one eDNA whose DNA sequence is 
different from all functionally characterized members of the 
CYP82E2 gene subfamily (Siminszky et a!. (2005) Proc. 
Isolation and Characterization of CYP82E5V2 
Nicotine Conversion in N. tomentosiformis and Various 
Tobacco Genotypes 
20 Nat!. Acad. Sci. U.S.A. 102: 14919-14924). A homology 
search against the GenBank database using the BLAST algo-
rithm reveals that the clone representing the unique DNA 
sequence shares a 99.7% nucleotide and a 99.2% predicted 
To assess the alkaloid composition of wild-type plants, 
concentrations of nicotine and nornicotine were determined 
in the green and cured leaves of N. tomentosiformis and 
various tobacco genotypes using gas chromatography. InN. 
25 
amino acid identity with the tobacco CYP82E5v1 eDNA of 
unknown function. According to the guidelines of the P450 
nomenclature committee, the eDNA was named 
NtabCYP82E5v2. The predicted amino acid sequence of 
tomentosiformis, nornicotine appears as the predominant 30 
alkaloid in both the green and cured leaves (Table 1). Con-
verter Burley cultivar DH-98-325-6 and converter Flue-
Cured cultivar SC58C contain low levels of nornicotine 
(about 3%) in the green leaves, but a large percentage (about 
35 
95 and 25%, respectively) nicotine content is metabolized 
into nornicotine once the leaves senesce (see, Table 1 ). Levels 
NtabCYP82E5v2 is 89.2, 91.9 and 91.3% identical to that of 
NtabCYP82E2, NtabCYP82E3 and NtabCYP82E4v2, 
respectively. 
NtabCYP82E5v2 Encodes for a Functional Nicotine Dem-
ethylase 
To determine whether NtabCYP82E5v2 encodes nicotine 
demethylase activity, the N.tabCYP82E5 eDNA is expressed 
in the WAT11 yeast strain. The WAT11 strain was engineered 
to provide high efficiency transgene expression and an opti-
mal redox environment for P450-mediated reactions by 
expressing the Arabidopsis P450 reductase gene, ATR1, 
under the transcriptional control of a galactose-inducible pro-
of nomicotine are low in both the green and cured leaves of 
nonconverter Burley and Flue-Cured cultivars DH98-325-5 
and SC58NC, respectively, although nicotine conversion 40 
slightly increases after curing. 
TABLE 1 
Alkaloid analysis of green and cured leaves of 
N tomentosiformis and various tobacco genotypes. 
% Nicotinea % Nornicotinea 
Plant Phenotype Green Curedc Green Curedc 
N. tomentosiformis GLC 0.003d 0.007 0.188 0.299 
(0.0002) (0.001) (0.022) (0.031) 
DH98-325-5 NC 1.243 1.332 0.032 0.040 
(0.334) (0.321) (0.006) (0.008) 
DH98-325-6 SLC 1.113 0.082 0.041 1.416 
(0.095) (0.019) (0.004) (0.187) 
SC58NC NC 1.422 1.487 0.032 0.039 
(0.127) (0.089) (0.004) (0.001) 
SC58C SLC 1.171 0.501 0.029 0.164 
"Percentage of leaf dry weight. 
b[% nornicotine (%nicotine+% nornicotinef1] x 100. 
"Leaves are treated with 0.2% ethephon and cured until they turned yellow. 
% Conversionb 
Green Cured 
98.4 97.7 
(2.4) (2.1) 
2.6 3.0 
(0.2) (0.3) 
3.5 94.4 
(0.1) (1.6) 
2.2 2.5 
(0.07) (0.1) 
2.4 24.7 
"'Mean over the alkaloid content of three plants, except SC58C where one plant was used due to the low frequency 
of corwersion. 
ev'alues in parenthesis represent standard error of the mean. 
Abbreviations: GLC, green-leaf converter; NC, noncorwerter; SLC, senescing-leaf corwerter. 
Isolation of the NtabCYP82E5v2 eDNA from Tobacco 
To identifY putative nicotine demethylase genes from 
tobacco, a PCR-based gene amplification strategy was used 
65 mater (Pompon eta!. (1996) Methods Enzymol. 272: 51-64). 
Microsomal fragments isolated from yeast expressing 
NtabCYP82E5v2 actively catalyze the N-demethylation of 
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nicotine. The Km and v max values for the NtabCYP82E5v2-
mediated nicotine demethylase reaction are 5.6±1.4 f.LM and 
0.7±0.02 nmol min- 1 mg- 1 protein (mean±standard error), 
respectively. In contrast, no nicotine demethylase activity is 
evident when microsomes isolated from yeast transformed 
with an empty plasmid are added to the catalytic assay. 
NtabCYP82E5v2 is Derived from Progenitor N. tomentosi-
formis 
As the allotetraploid genome of tobacco consists of two 
genetic components, the S genome donated by N. sylvestris 
and the T genome derived from N. tomentosiformis, which of 
the two progenitor species contributed NtabCYP82E5v2 to 
tobacco is unknown. To this end, CYP82E2-specific primers 
were designed to amplify a genomic fragment of the 
CYP82E5 genes from tobacco and the NtabCYP82E5v2-
donating progenitor. PCR amplifications produce a distinct 
2243 bp product when genomic DNA isolated from tobacco 
10 
15 
42 
TABLE 2-continued 
Absolute quantification oftbe CYP82E4v2 and CYP82E5v2 
eDNA derived from tbe green and cured leaves of N. tomentosiformis 
and different tobacco genotypes by quantitative real-time 
polymerase chain reaction analysis. 
CYP82E4v2 CYP82E5v2 
Green Cured Green Cured 
Sample Pg 
DH98-325-5 0.0004a 0.007b 0.08c 0.26c 
(0.0001) 0.003) (0.01) (0.17) 
DH98-325-6 0.004b 26.09e 0.137c 0.311c 
(0.001) (3.50) (0.003) (0.109) 
SC58NC 0.0006a 0.005b 0.070c 0.067c 
(0.0001) (0.003) (0.012) (0.005) 
SC58C 0.0006a 1.81d 0.11c 0.083c 
*Means are for lleaf of3 independent plants, 3 eDNA measurements per sample (n = 9), 
except SC58C where one plant was used (n = 3). 
*Numbers followed by different letters are significantly different according to Fisher's 
protected LSD (0.05). 
or N. tomentosiformis is used as template, but amplicons are 20 
not detected when genomic DNA of N. sylvestris is amplified 
indicating that NtabCYP82E5v2 was derived from N. tomen-
tosiformis. DNA sequence analysis reveals that the genomic 
fragments ofNtabCYP82E5v2 and NtomCYP82E5 contain a 
1054 bp intron flanked by a 604 bp 5' and a 585 bp 3' coding 25 
Low levels of NtabCYP82E5v2 express in the green or 
yellow leaves of all tobacco cultivars (see, Table 2). The 
expression ofNtabCYP82E5v2 significantly increased in the 
cured versus green leaves of converter and nonconverter Bur-
ley cultivars but remained unchanged in Flue-Cured tobacco. 
In the green leaves of N. tomentosiformis, expression of 
NtomCYP82E5 was higher than in tobacco, but no difference 
was noted between the cured leaves of the two species (Table 
2). To compare the expression levels ofCYP82E5v2 with that 
region and differ at 15 positions of which nine and six are 
located within the coding region and intron, respectively. 
Furthermore, the coding regions often randomly selected 
genomic clones isolated from tobacco share 100% nucleotide 
identity with the NtabCYP82E5v2 eDNA suggesting that 
NtabCYP82E5v2 is the only CYP82E5 variant located in 
DH98-325-6 tobacco. 
NtabCYP82E5v2 is Expressed at Low Levels in the Green 
and Yellow Leaves 
To investigate the catalytic role of CYP82E5 in planta, the 
transcriptional profile of CYP82E5v2 in the green and 
senescing leaves of converter (DH98-325-6) and noncon-
verter (DH98-325-5) Burley, converter and nonconverter 
Flue-Cured (SC58) tobacco, and N. tomentosiformis was 
determined using quantitative real-time (qrt)-PCR analysis. 
TABLE2 
Absolute quantification oftbe CYP82E4v2 and CYP82E5v2 
eDNA derived from tbe green and cured leaves of N. tomentosiformis 
and different tobacco genotypes by quantitative real-time 
polymerase chain reaction analysis. 
CYP82E4v2 CYP82E5v2 
Green Cured Green Cured 
Sample Pg 
N. tomentosiformis 0.35c 17.94e 1.73d 0.18c 
(0.16) (2.57) (0.72) (0.09) 
30 ofCYP82E4v2, a previously characterized nicotine demethy-
lase gene whose transcription was shown to be sharply 
upregulated in senescing leaves of N. tomentosiformis and 
converter tobacco (Gavilano eta!. (2007) J. Biol. Chern. 282: 
249-256), the transcript accumulation of CYP82E4v2 was 
35 compared in the same extracts used for quantifying the 
CYP82E5v2 mRNA. Transcription of NtabCYP82E5v2 is 
significantly higher than that ofNtabCYP82E4v2 in the green 
leaves of all tobacco cultivars, N. tomentosiformis and in the 
cured leaves of nonconverter tobacco plants. However, the 
40 trend is reversed in the cured leaves of converter tobacco and 
N. tomentosiformis (Table 2). Of the two nicotine demethy-
lase genes characterized thus far CYP82E4v2 is the dominant 
factor in senescence-inducible nornicotine production inN. 
tomentosiformis and tobacco. In addition, the activity of 
45 NtabCYP82E5v2 is the key determinant of nicotine conver-
sion in the green leaves of tobacco. 
50 
EXAMPLE2 
Sequence Identity to Cytochrome P450 Gene Family 
Members 
Even though CYP82E5v2 and CYP82E4v2 are both nico-
tine demethylases, they have less sequence homology to each 
other than CYP82E5v2 does to CYP82E3, for example. 
TABLE3 
Amino acid sequence identity shared between tbe CYP82E4v2 nicotine demetbylase enzyme and 
tbe otber CYP82E2 proteins tbat have been assayed for nicotine demetbylase activity. 
CYP82E4v6 CYP82E4v12 58-166 CYP82E3 CYP82E2v1 CYP82E2v2 CYP82E5v2 
CYP82E4v2 
SEQIDNO: 13 
99.6% 99.4% 94.8% 94.2% 92.6% 
CYP82E5v2 and CYP82E4v2 are the only proteins represented that have nicotine demethylase activity. 
92.6% 91.1% 
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TABLE4 
Amino acid sequence identity shared between the CYP82E4v2 
nicotine demethylase enzyme and other CYP82E2 proteins. 
CYP82E5v2 
SEQ IDNO: 2 
CYP82E4v2 
91.1% 
CYP82E3 CYP82E2 
91.9% 91.3% 
CYP82E5v2 and CYP82E4v2 are the only proteins represented that have nicotine demethy-
lase activity. 
TABLES 
44 
location using the complementary primers, combined with 
visual inspection of the corresponding chromatograms dis-
tinguishes plants that are truly heterozygous for a mutation in 
CYP82E4v2, and differentiate these true heterozygotes from 
artifactual sequence anomalies. 
Mutations in CYP82E4v2 
High-throughput sequence analysis of 672 independent 
M1 plants resulted in the identification of eleven individuals 
possessing point mutations within the CYP82E4v2 gene (see, 
Table 6). Six of the eleven plants identified carrying 
CYP82E4v2 mutations are homozygous for the mutant allele 
Expression profiles for the CYP82E2 gene family members 
that have been assayed for nicotine demethylase activity. 
CYP82E4v2 CYP82E4v6 CYP82E4v12 58-166 CYP82E3 CYP82E2v1 CYP82E2v2 CYP82E5v2 
Extremely Low in Not Extremely Low In Extremely Not Low in 
Low in Green Leaf; Reported Low In Both Low in Reported Green Leaf; 
Green Leaf; High in Both Green and Green Leaf; Very Low in 
Extremely Ethylene- Green and Ethylene- Extremely Ethylene-
High in Induced Ethylene- Induced High in Induced 
Ethylene- Senescent Induced Senescent Ethylene- Senescent 
Induced Leaf Senescent Leaves Induced Leaf 
Senescent Leaves Senescent 
Leaf Leaf 
CYP82E5v2 and CYP82E4v2 are the only proteins represented that were positive for nicotine demethylase activity. 
EXAMPLE3 
Mutations IN CYP82E4v2 AND CYP82E5v2 30 
Obtaining EMS-Derived Variants ofCYP82E4v2 
To facilitate the introduction of random mutations into the 
tobacco genome, thousands of seeds of the strong Converter 
35 
Burley line DH98-325-6 were treated with the chemical 
mutagene ethyl methane sulphonate (EMS). Approximately 
4000 mutagenized plants (M0 generation) were grown in the 
field and allowed to self-pollinate. Several capsules from each 
individual plant were combined to create discrete M1 seed 40 
populations, each corresponding to an individual M0 plant. 
Genomic DNAs were isolated from young leaf tissue of a 
single greenhouse-grown M 1 plant from each M1 seed pool. 
To identifY plants carrying mutations in the CYP82E4v2 
gene, specific primers were designed to independently 45 
amplify each of the gene's two exons. DNA sequence infor-
mation was obtained using 96-well high-throughput 
sequence analysis of the amplification products. The com-
plete analysis of 96 individual plants involved 4 separate 
96-well sequencing reactions: forward and reverse sequenc- 50 
ing of the exon 1 amplification product, and forward and 
reverse sequencing of the ex on 2 PCR product. 
Mutations were identified by conducting a multi-sequence 
aligmnent of all 96 sequences for a given run and looking for 
deviations from the wild-type sequence. Any given mutation 55 
that occurred in a parental M0 plant would be expected to be 
segregating in 1:2:1 ratio in the M1 generation for the mutant 
versus wild-type alleles. M1 plants that are homozygous for 
an EMS-induced mutation are readily recognized as poly-
morphisms deviating from the wild type sequence, verified in 60 
both directions. M 1 plants that are heterozygous for a muta-
tion in CYP82E4v2 would be expected to have the mutant and 
wild type alleles each representing 50% of the amplification 
product. Upon sequencing, the location of such a mutation 
would be expected to be annotated as an "N", since the fluo- 65 
rescence reading at that site would be a mixture of two alter-
native bases. The appearance of an "N" at the same nucleotide 
(see, Table 6). All eleven mutations result in changes in the 
predicted amino acid sequence of the encoded protein. 
TABLE6 
M 1 Lines of EMS Treated DH98-325-6 Plants 
Possessing Mutations in the CYP82E4v2 Gene. 
Nucleotide Amino Acid Zygosity of Mutant 
Plant Line Mutation* Change** Allele 
DH98-325-6 #101 C1372T P458S Homozygous 
DH98-325-6 #121 G1092T K364N Homozygous 
DH98-325-6 #164 C113T P38L Homozygous 
DH98-325-6 #321 G601A E201K Heterozygous 
DH98-325-6 #377 G506A R169Q Heterozygous 
DH98-325-6 #569 G1375A G459R Heterozygous 
DH98-325-6 #506 G886A E296K Heterozygous 
DH98-325-6 #453 C1280T T4271 Heterozygous 
DH98-325-6 #775 G986A W329Stop Homozygous 
DH98-325-6 #610 G1126A V376M Homozygous 
DH98-325-6 #761 G511A D171N Homozygous 
*Nucleotide location is in reference to the ATG initiator codon of the CYP82E4v2 eDNA 
(see SEQ ID NO: 50). Nucleotide to the left of the number represents the wild type residue, 
whereas the nucleotide on the right indicates the mutant residue (e.g. C1372T means that the 
C residue normally located at position 1372 was mutated to aT residue). 
**Amino acid location is in reference to the initiator methionine of the CYP82E4v2 
polypeptide (see SEQ ID NO: 13). Amino acid to the left of the number represents the wild 
type residue, whereas the amino acid on the right indicates the residue produced by the 
mutant allele (e.g. P458S means that the Proline residue normally located at position 458 of 
the protein sequence has been changed to a Serine). "Stop" indicates the introduction of a 
premature stop codon. 
Plant #775 possesses a mutation at codon 329 which 
changes a tryptophan codon (TGG) into a premature stop 
codon (TAG). This mutation renders the encoded protein 
completely nonfunctional given that the essential heme-bind-
ing domain and other highly conserved regions of the enzyme 
are located downstream of codon 329. Other plants contain 
mutations affecting highly conserved motifs shared by the 
vast majority of P450 enzymes include: plant #1 01 (where a 
conserved Pro residue immediately adjacent to the heme-
binding Cys amino acid is change to a Ser); plant #164 (Pro 
residue within the highly conserved Pro-rich "hinge" region 
of the protein changed to a Leu); and plant #569 (Gly residue 
that's part of the very highly conserved heme-binding motif 
changed to an Arg). 
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Alkaloid Analysis ofCYP82E4v2 Variants 
46 
render the product completely nonfunctional. The G to A 
mutation at position 1266 changes a Trp codon (TGG) into a 
premature stop codon (TGA). The predicted CYP82E5v2 
protein produced from this truncated reading frame lacks the 
final 96 amino acids of the enzyme, a region that includes the 
essential heme-binding domain. Without being limited by 
mechanism, this truncated protein is probably incapable of 
catalyzing the oxidative elimination of theN' methyl group of 
nicotine to form nomicotine. Whatever the mechanism, the 
An alkaloid analysis was conducted on cured leaves of 
variant individuals to assess the effect of the mutation on the 
metabolic conversion of nicotine to nornicotine. As shown in 
Table 7, three individuals (#101, #121 and #775) show con-
version rates similar to nonconverter control plants grown 
from seed lots that had been screened to eliminate converter 
individuals (TN90 LC plants). The variant CYP82E4v2 
enzymes produced in these plants are completely (or nearly 
completely) nonfunctional. Two plants (#164 and #761) dis-
play high conversion rates and have no detrimental effect on 
enzyme activity. This result for plant #164 is surprising given 
that it contains a Pro to Leu mutation within one of the 
residues defining the highly conserved Pro-rich hinge motif. 
The Val to Met modification at residue 376 partially inhibits 
enzyme function as the homozygous mutant plant (#610) 
shows an intermediate conversion phenotype ( 41.5% ). 
10 #1013 plant has a nonfunctional CYP82E5v2 allele. Plant 
#680 possesses a mutation that changes a Pro residue at 
position 449 to a Leu. This Pro is well conserved in plant 
P450s and lies immediately adjacent to the F-x-x-G-x-R-x-
15 C-x -G motif that defines the heme binding region. The muta-
tion found in plant #680 has a negative impact on enzyme 
function. 
TABLE 7 
Alkaloid Content as Percent Dry Weight of M 1 Plants 
Homozygous for Mutations in the CYP82E4v2 Gene 
% 
Plant Nicotine Nornicotine Anabasine Anatabine Conversion* 
DH98-325-6 #101 2.17 0.0376 0.00514 0.0384 1.7% 
DH98-325-6 #121 2.5 0.0333 0.00557 0.043 1.3% 
DH98-325-6 #164 0.216 0.84 0.00499 0.0532 79.5% 
DH98-325-6 #610 0.214 0.152 0.00429 0.0121 41.5% 
DH98-325-6 #761 0.214 0.999 0.00429 0.0426 82.4% 
DH98-325-6 #775 0.505 0.0159 0.00417 0.0136 3.1% 
SC58 CtCt (Control)t 0.206 0.565 0.00412 0.0197 73.3% 
TN90 LC (Control) 3.11 0.0647 0.00901 0.0487 2.0% 
TN90 LC (Control) 2.46 0.0521 0.00846 0.0417 2.1% 
*[% nornicotine/(% nicotine+% nornicotine)] x 100 
t A corwerter plant of flue-cured genotype SC58 is used as a strong converter control; two plants of genotype 
TN90 selected from lots screened for low corwerters (LC) are used as non converter controls. 
The substitution of the Lys residue at position 364 to anAsn 
of plant #121 within this plant does not occur in any motif 
conserved among P450 enzymes, nor within any region pre-
dicted by Xu eta!. (Physiologia Plantarum 129: 307-319, 40 
2007) to be a substrate recognition site. A BLAST alignment 
against protein sequences deposited in GenBank reveals sev-
eral P450s that possess an Asn residue at the analagous posi-
tion (e.g. the CYP82A1 gene of Pea-accession nnmber 
Q43068). The variant CYP82E4v2 gene in plant #121 is 45 
completely inactive. Another anomaly with plant #121 lies in 
the nature of EMS-induced mutations. EMS is known to 
induce mutations through the alkylation ofG residues, result-
ing in G to A or C to T transition mutations (Anderson, 
50 
Methods Cell Biol. 48:31-58, 1995). Very rarely does EMS 
lead to a G to T transversion mutation such as that found in 
plant #121 (see, Table 3). All other mutations described for 
either the CYP82E4v2 or CYP82E5v2 genes are the expected 
G to A or C to T transition mutations. 55 
Mutations in CYP82E5v2 
A similar high-throughput sequencing strategy was used to 
identify mutations in CYP82E5v2, the other confirmed nico-
tine N-demethylase gene that is found within the tobacco 
60 
genome. A screen of768 M1 plants revealed 11 individuals 
possessing mutations in CYP82E5v2 (see, Table 8). Three 
plants (#744, #561 and #340) contain silent nucleotide sub-
stitutions that did not alter the predicted protein sequence. Of 
the eight mutations that lead to changes in the protein 65 
sequence, two are of particular note. Plant #1 013 contains a 
mutation that would lead to a truncated product that should 
TABLES 
M 1 Lines of EMS Treated DH98-325-6 Plants 
Possessing Mutations in the CYP82E5v2 Gene 
Nucleotide Amino Acid Zygosity of Mutant 
Plant Line Mutation* Change** Allele 
DH98-325-6 #198 C703T P235S Heterozygous 
DH98-325-6 #680 C1346T P449L Homozygous 
DH98-325-6 #744 G558A None Homozygous 
DH98-325-6 #163 C521T S174L Heterozygous 
DH98-325-6 #561 G1458A None Heterozygous 
DH98-325-6 #154 C1229T A410V Heterozygous 
DH98-325-6 #340 G1248A None Heterozygous 
DH98-325-6 #780 G672A M2241 Heterozygous 
DH98-325-6 #799 C215T P72L Heterozygous 
DH98-325-6 #540 C427T L143F Heterozygous 
DH98-325-6 #1013 G1266A W422Stop Homozygous 
*Nucleotide location is in reference to the ATG initiator codon of the CYP82E5v2 eDNA 
(see SEQ ID NO: 1). Nucleotide to the left of the number represents the wild type residue, 
whereas the nucleotide on the right indicates the mutant residue (e.g. C703T means that the 
C residue normally located at position 703 was mutated to a T residue). 
**Amino acid location is in reference to the initiator methionine of the CYP82E5v2 
polypeptide (see SEQ ID NO: 2). Amino acid to the left of the number represents the wild 
type residue, whereas the amino acid on the right indicates the residue produced by the 
mutant allele (e.g. P235S means that the Proline residue normally located at position 235 of 
the protein sequence has been changed to a Serine). "Stop" indicates the introduction of a 
premature stop codon. "None" indicates mutations resulting in silent substitutions that did 
not alter the predicted amino acid sequence. 
Plants with Mutations in CYP82E4v2 and CYP82E5v2 
Tobacco plant lines are generated that show uniformity and 
stability within the limits of environmental influence for 
reduced conversion of nicotine to nornicotine at levels of 
US 9,228,194 B2 
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about 0.5% when a plant with a mutation that inhibits nicotine 
demethylase activity of CYP82E4v2 is crossed with a plant 
having a mutation that inhibits nicotine demethylase activity 
ofCYP82E5v2. 
TABLE 9-continued 
Illustrative Crosses ofDH98-325-6 Plants Possessing 
Mutations in the CYP82E5v2 and CYP82E4v2 Genes 
An illustrative cross is between a CYP82E4v2 mutant plant 
(of Table 9) and a CYP82E5v2 mutant plant (of Table 9). 
TABLE9 
10 
CYP82E4v2 
DH98-325-6 #101 
DH98-325-6 #121 
DH98-325-6 #775 
Illustrative Crosses ofDH98-325-6 Plants Possessing 
Mutations in the CYP82E5v2 and CYP82E4v2 Genes 
CYP82E5v2 
DH98-325-6 #198 
DH98-325-6 #680 
DH98-325-6 #163 
DH98-325-6 #154 
DH98-325-6 #780 
DH98-325-6 #799 
DH98-325-6 #540 
DH98-325-6 #1013 
All publications and patent applications mentioned in the 
specification are indicative of the level of those skilled in the 
art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli-
15 cation was specifically and individually indicated to be incor-
porated by reference. 
<160> NUMBER OF SEQ ID NOS, 50 
<210> SEQ ID NO 1 
<211> LENGTH, 1554 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 1 
Although the foregoing invention has been described in 
some detail by way of illustration and example for purposes 
of clarity of understanding, it will be obvious that certain 
20 changes and modifications may be practiced within the scope 
of the appended claims. 
atggtttctc ccgtagaagc cattgtagga ctagtaaccc ttacacttct cttctacttc 60 
ctatggccca aaaaatttca aataccttca aaaccattac caccgaaaat tcccggaggg 120 
tggccggtaa tcggccatct tttctacttc gatgatgacg gcgacgaccg tccattagct 180 
cgaaaactcg gagacttagc tgacaaatac ggcccggttt tcactttccg gctaggcctt 240 
ccgcttgtgt tagttgtaag cagttacgaa gctgtaaaag actgcttctc tacaaatgac 300 
gccattttct ccaatcgtcc agcttttctt tacggtgaat accttggcta cagtaatgcc 360 
atgctatttt tgacaaaata cggaccttat tggcgaaaaa atagaaaatt agtcattcag 420 
gaagttctct ctgctagtcg tctcgaaaaa ttgaagcacg tgagatttgg taaaattcaa 480 
acgagcatta agagtttata cactcgaatt gatggaaatt cgagtacgat aaatctaact 540 
gattggttag aagaattgaa ttttggtctg atcgtgaaaa tgatcgctgg gaaaaattat 600 
gaatccggta aaggagatga acaagtggag agatttagga aagcgtttaa ggattttata 660 
attttatcaa tggagtttgt gttatgggat gcttttccaa ttccattgtt caaatgggtg 720 
gattttcaag gccatgttaa ggccatgaaa aggacattta aggatataga ttctgttttt 780 
cagaattggt tagaggaaca tgtcaagaaa agagaaaaaa tggaggttaa tgcacaaggg 840 
aatgaacaag atttcattga tgtggtgctt tcaaaaatga gtaatgaata tcttgatgaa 900 
ggttactctc gtgatactgt cataaaagca acagtgttta gtttggtctt ggatgctgcg 960 
gacacagttg ctcttcacat gaattgggga atggcattac tgataaacaa tcaacatgcc 1020 
ttgaagaaag cacaagaaga gatcgataaa aaagttggta aggaaagatg ggtagaagag 1080 
agtgatatta aggatttggt ctacctccaa gctattgtta aagaagtgtt acgattatat 1140 
ccaccaggac ctttattagt acctcatgaa aatgtagagg attgtgttgt tagtggatat 1200 
cacattccta aagggactag actattcgcg aacgttatga aattgcagcg cgatcctaaa 1260 
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ctctggtcaa atcctgataa gtttgatcca gagagattct tcgctgatga tattgactac 
cgtggtcagc actatgagtt tatcccattt ggttctggaa gacgatcttg tccggggatg 
acttatgcat tacaagcgga acacctaaca atagcacatt tgatccaggg tttcaattac 
aaaactccaa atgacgagcc cttggatatg aaggaaggtg caggattaac tatacgtaaa 
gtaaatcctg tagaagtgac aattacggct cgcctggcac ctgagcttta ttaa 
<210> SEQ ID NO 2 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 2 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
50 
1320 
1380 
1440 
1500 
1554 
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325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 3 
<211> LENGTH, 1054 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana tabacum 
<400> SEQUENCE, 3 
gtaagttcat tttcattttt cattattcag 
taatttaagt aattagatta tctaaatact 
atgataaatg gaaaaaagat gagaattctt 
agttaaaagt gcttcaccaa aggggacttt 
tagatgaaag agtatttatc acttcacgaa 
cagttataat tgatagaata aaacttcatt 
agggacttct tctctttttt ttagggagaa 
atgttttttt tttcttctat ttctaataat 
tagcagcaat atagtcaaag ctaatatcca 
aaattatata tacgggtatt aaataataac 
tgggtaaata ttacaacaac aacaactgac 
agggtagtgt gtatgcagac cttaccccta 
agaccctcgg ctcaagaaaa caaaaagaga 
taggtaaatg ttattttatt gaattaaaga 
atttgatttt acactagata aatttgacct 
tgaattttag atttaaaaaa aaaattcatt 
actatactaa atagaacaag gttcggcaga 
tctgattttg aggaatagac 
aaggatgatt atatatagta 
tgtgcctcga ctaatctata 
tcctcatagc tcaagttaga 
ctctgatgat aaaagtaaat 
actcccattg agcataaaaa 
attctttaat tgtttgttaa 
aatggttctt gaatcaggtc 
tgttatttgg ttttcgaaca 
attattattt ataggatata 
tcagtgaaat tttactagtg 
ccccgaagga gtagagggat 
caatatcagt accaccacag 
tgaaatatac aggtaaggta 
cgtacatctc taagagaaag 
agtataatga gatgtgcata 
tagtgacact aacctacttt 
aggttaataa 
aaaatgtaga 
tatctttggg 
agtttgatta 
gagatataac 
aaaaagtaaa 
atatagattc 
gttgactttg 
agttatactg 
ctttttttat 
gggtatgggg 
tgtttccgaa 
atcatattat 
taaaacgtgt 
ctgaaataaa 
cttgacaatt 
tgcattgaat 
52 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
53 
tatccttttt aattttattc taatttgtct acag 
<210> SEQ ID NO 4 
<211> LENGTH, 2608 
<212> TYPE, DNA 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 4 
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atggtttctc ccgtagaagc cattgtagga ctagtaaccc ttacacttct cttctacttc 
ctatggccca aaaaatttca aataccttca aaaccattac caccgaaaat tcccggaggg 
tggccggtaa tcggccatct tttctacttc gatgatgacg gcgacgaccg tccattagct 
cgaaaactcg gagacttagc tgacaaatac ggcccggttt tcactttccg gctaggcctt 
ccgcttgtgt tagttgtaag cagttacgaa gctgtaaaag actgcttctc tacaaatgac 
gccattttct ccaatcgtcc agcttttctt tacggtgaat accttggcta cagtaatgcc 
atgctatttt tgacaaaata cggaccttat tggcgaaaaa atagaaaatt agtcattcag 
gaagttctct ctgctagtcg tctcgaaaaa ttgaagcacg tgagatttgg taaaattcaa 
acgagcatta agagtttata cactcgaatt gatggaaatt cgagtacgat aaatctaact 
gattggttag aagaattgaa ttttggtctg atcgtgaaaa tgatcgctgg gaaaaattat 
gaatccggta aaggagatga acaagtggag agatttagga aagcgtttaa ggattttata 
attttatcaa tggagtttgt gttatgggat gcttttccaa ttccattgtt caaatgggtg 
gattttcaag gccatgttaa ggccatgaaa aggacattta aggatataga ttctgttttt 
cagaattggt tagaggaaca tgtcaagaaa agagaaaaaa tggaggttaa tgcacaaggg 
aatgaacaag atttcattga tgtggtgctt tcaaaaatga gtaatgaata tcttgatgaa 
ggttactctc gtgatactgt cataaaagca acagtgtttg taagttcatt ttcatttttc 
attattcagt ctgattttga ggaatagaca ggttaataat aatttaagta attagattat 
ctaaatacta aggatgatta tatatagtaa aaatgtagaa tgataaatgg aaaaaagatg 
agaattcttt gtgcctcgac taatctatat atctttggga gttaaaagtg cttcaccaaa 
ggggactttt cctcatagct caagttagaa gtttgattat agatgaaaga gtatttatca 
cttcacgaac tctgatgata aaagtaaatg agatataacc agttataatt gatagaataa 
aacttcatta ctcccattga gcataaaaaa aaaagtaaaa gggacttctt ctcttttttt 
tagggagaaa ttctttaatt gtttgttaaa tatagattca tgtttttttt ttcttctatt 
tctaataata atggttcttg aatcaggtcg ttgactttgt agcagcaata tagtcaaagc 
taatatccat gttatttggt tttcgaacaa gttatactga aattatatat acgggtatta 
aataataaca ttattattta taggatatac tttttttatt gggtaaatat tacaacaaca 
acaactgact cagtgaaatt ttactagtgg ggtatgggga gggtagtgtg tatgcagacc 
ttacccctac cccgaaggag tagagggatt gtttccgaaa gaccctcggc tcaagaaaac 
aaaaagagac aatatcagta ccaccacaga tcatattatt aggtaaatgt tattttattg 
aattaaagat gaaatataca ggtaaggtat aaaacgtgta tttgatttta cactagataa 
atttgacctc gtacatctct aagagaaagc tgaaataaat gaattttaga tttaaaaaaa 
aaattcatta gtataatgag atgtgcatac ttgacaatta ctatactaaa tagaacaagg 
ttcggcagat agtgacacta acctactttt gcattgaatt atccttttta attttattct 
aatttgtcta cagagtttgg tcttggatgc tgcggacaca gttgctcttc acatgaattg 
54 
1054 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
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gggaatggca ttactgataa acaatcaaca tgccttgaag aaagcacaag aagagatcga 
taaaaaagtt ggtaaggaaa gatgggtaga agagagtgat attaaggatt tggtctacct 
ccaagctatt gttaaagaag tgttacgatt atatccacca ggacctttat tagtacctca 
tgaaaatgta gaggattgtg ttgttagtgg atatcacatt cctaaaggga ctagactatt 
cgcgaacgtt atgaaattgc agcgcgatcc taaactctgg tcaaatcctg ataagtttga 
tccagagaga ttcttcgctg atgatattga ctaccgtggt cagcactatg agtttatccc 
atttggttct ggaagacgat cttgtccggg gatgacttat gcattacaag cggaacacct 
aacaatagca catttgatcc agggtttcaa ttacaaaact ccaaatgacg agcccttgga 
tatgaaggaa ggtgcaggat taactatacg taaagtaaat cctgtagaag tgacaattac 
ggctcgcctg gcacctgagc tttattaa 
<210> SEQ ID NO 5 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 5 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Ser Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
56 
2100 
2160 
2220 
2280 
2340 
2400 
2460 
2520 
2580 
2608 
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Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 6 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
58 
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59 
-continued 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Leu Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 7 
<211> LENGTH, 517 
60 
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61 
-continued 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 7 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Leu Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
62 
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63 
-continued 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 8 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 8 
Met Val Ser Pro Val Glu Ala Ile Val 
1 5 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys 
20 25 
Gly Leu Val Thr Leu 
10 
Phe Gln Ile Pro Ser 
30 
Thr Leu 
15 
Lys Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
64 
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65 
-continued 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Val Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 9 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 9 
Met Val Ser Pro Val Glu Ala Ile Val 
1 5 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys 
20 25 
Gly Leu Val Thr Leu 
10 
Phe Gln Ile Pro Ser 
30 
Thr Leu 
15 
Lys Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
66 
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67 
-continued 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Ile 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
68 
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<210> SEQ ID NO 10 
<211> LENGTH, 517 
<212> TYPE, PRT 
69 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 10 
Met Val Ser Pro Val Glu Ala Ile Val 
1 5 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys 
20 25 
-continued 
Gly Leu Val Thr Leu Thr Leu 
10 15 
Phe Gln Ile Pro Ser Lys Pro 
30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Leu Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
70 
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71 
-continued 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 11 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 11 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Phe Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
72 
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-continued 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Phe Ala Asp Asp Ile Asp Tyr Arg Gly Gln His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Ala Glu His Leu Thr Ile Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Leu 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Val Thr Ile Thr Ala Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 12 
<211> LENGTH, 421 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 12 
Met Val Ser Pro Val Glu Ala Ile Val Gly Leu Val Thr Leu Thr Leu 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Pro Lys Lys Phe Gln Ile Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
74 
US 9,228,194 B2 
75 
-continued 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Leu Thr Lys Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Leu Lys His Val Arg Phe Gly Lys Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Ser Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Arg Lys Ala Phe Lys Asp Phe Ile Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Val Lys Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Gln Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Met Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln His Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Lys Lys Val 
340 345 350 
Gly Lys Glu Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu 
420 
<210> SEQ ID NO 13 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 13 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
76 
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-continued 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
78 
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79 
-continued 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 14 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 14 
Met Leu Ser Pro Ile Glu Ala Ile Val 
1 5 
Leu Phe Phe Phe Leu Trp Thr Lys Lys 
20 25 
Gly Leu Val Thr Phe 
10 
Ser Gln Lys Pro Ser 
30 
Thr Phe 
15 
Lys Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
80 
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Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Ser Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 15 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 15 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
82 
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Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Asn Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 16 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
84 
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-continued 
<400> SEQUENCE, 16 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Leu Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
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Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 17 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 17 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Lys Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
88 
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260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 18 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 18 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
90 
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Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Gln Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
92 
<210> SEQ ID NO 19 
<211> LENGTH, 517 
<212> TYPE, PRT 
93 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 19 
US 9,228,194 B2 
-continued 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
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Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Arg Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 20 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 20 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
96 
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Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Lys Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp 
485 
Thr Ile Arg Lys Val 
500 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 21 
<211> LENGTH, 517 
<212> TYPE, PRT 
Glu Pro Leu Asp 
Asn Pro Val Glu 
505 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 21 
Met Lys Glu Gly Ala Gly Ile 
490 495 
Leu Ile Ile Ala Pro Arg Leu 
510 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
98 
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85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Ile Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
100 
US 9,228,194 B2 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 22 
<211> LENGTH, 328 
<212> TYPE, PRT 
101 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 22 
-continued 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn 
325 
<210> SEQ ID NO 23 
<211> LENGTH, 517 
<212> TYPE, PRT 
102 
US 9,228,194 B2 
103 
-continued 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 23 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Met Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
104 
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105 
-continued 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp 
485 
Thr Ile Arg Lys Val 
500 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 24 
<211> LENGTH, 517 
<212> TYPE, PRT 
Glu Pro Leu Asp 
Asn Pro Val Glu 
505 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 24 
Met Lys Glu Gly Ala Gly Ile 
490 495 
Leu Ile Ile Ala Pro Arg Leu 
510 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
106 
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-continued 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 25 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 25 
Met Leu Ser Pro Ile Glu Ala Ile Val 
1 5 
Leu Phe Phe Phe Leu Trp Thr Lys Lys 
20 25 
Gly Leu Val Thr Phe 
10 
Ser Gln Lys Pro Ser 
30 
Thr Phe 
15 
Lys Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
108 
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109 
-continued 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
110 
<210> SEQ ID NO 26 
<211> LENGTH, 517 
<212> TYPE, PRT 
111 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 26 
US 9,228,194 B2 
-continued 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
112 
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113 
-continued 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Leu 
405 410 415 
Arg Asp Pro Lys Leu Trp Pro Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 27 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 27 
Met Leu Ser Pro Ile Glu Ala Ile Val 
1 5 
Leu Phe Phe Phe Leu Trp Thr Lys Lys 
20 25 
Gly Leu Val Thr Phe 
10 
Ser Gln Lys Pro Ser 
30 
Thr Phe 
15 
Lys Pro 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
114 
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115 
-continued 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Glu Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Cys Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Pro Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 28 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 28 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asn Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
116 
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-continued 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Lys Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Arg Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Ile Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Ile Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Ile Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
Tyr Ile Ser Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Pro Asn Pro Asp Asn Phe Asp Pro Glu Arg 
420 425 430 
Phe Val Ala Ala Gly Ile Asp Phe Arg Gly Gln His Tyr Glu Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Ser Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
118 
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Thr Ile Arg Lys Val Asn Pro Val Glu Val Ile Ile Met Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 29 
<211> LENGTH, 518 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 29 
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
120 
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-continued 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
Leu Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 30 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 30 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
122 
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-continued 
195 200 205 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp 
485 
Thr Ile Arg Lys Val 
500 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 31 
<211> LENGTH, 517 
<212> TYPE, PRT 
Glu Ala Leu Asp 
Asn Pro Val Glu 
505 
<213> ORGANISM: Nicotiana tabacum 
<400> SEQUENCE, 31 
Met Lys Glu Gly Ala Gly Ile 
490 495 
Leu Ile Ile Thr Pro Arg Leu 
510 
Met Leu Ser Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
124 
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His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Leu Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Ile Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
126 
465 
Lys Thr Pro Asn Asp 
485 
Thr Ile Arg Lys Val 
500 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 32 
<211> LENGTH, 21 
<212> TYPE, DNA 
127 
470 
Glu Ala Leu Asp 
Asn Pro Val Glu 
505 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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475 480 
Met Lys Glu Gly Ala Gly Ile 
490 495 
Leu Ile Ile Thr Pro Arg Leu 
510 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 32 
tggaattatg cccatcctac a 
<210> SEQ ID NO 33 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 33 
cattagtggt tgcacctgag g 
<210> SEQ ID NO 34 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 34 
gatgagatgt gtgcatactt g 
<210> SEQ ID NO 35 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 35 
ccaaattaga aaaactcgta ctg 
<210> SEQ ID NO 36 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 36 
attgtaggac tagtaaccct tacac 
<210> SEQ ID NO 37 
<211> LENGTH, 21 
128 
21 
21 
21 
23 
25 
129 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 37 
gaggcacaaa gaattctcat c 
<210> SEQ ID NO 38 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 38 
gagtagaggg attgtttccg 
<210> SEQ ID NO 39 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 39 
gtacaatcaa gataaaacat ctaagg 
<210> SEQ ID NO 40 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 40 
cggtgaatac cttggctaca g 
<210> SEQ ID NO 41 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 41 
aattgtcact tctacaggat ttact 
<210> SEQ ID NO 42 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 42 
atggtttttc cggtagaa 
<210> SEQ ID NO 43 
<211> LENGTH, 18 
<212> TYPE, DNA 
130 
21 
20 
26 
21 
25 
18 
131 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 43 
ttaataaagc tcaggtgc 
<210> SEQ ID NO 44 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 44 
acgtgatcct aaactctggt ctg 
<210> SEQ ID NO 45 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 45 
gcctgcacct tccttcatg 
<210> SEQ ID NO 46 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 46 
gggatgactt atgcattaca age 
<210> SEQ ID NO 47 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 47 
aattgtcact tctacaggat ttact 
<210> SEQ ID NO 48 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 48 
ggtgtccaca gacttcgtgg 
<210> SEQ ID NO 49 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
132 
18 
23 
19 
23 
25 
20 
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<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 49 
gactcctcac agcagcacca 
<210> SEQ ID NO 50 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 3 
20 
atg ctt tct ccc ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc ccc gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg ega aaa aat ega aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act ega att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
134 
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gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta ega tta tat cca cca gga cct 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga ega tct tgt cca ggg atg act tat gca ttg 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag ccc ttg gat atg aag gaa ggt gca ggc ata 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 
aagataattg actgattgtc cc 
136 
768 
816 
864 
912 
960 
1008 
1056 
1104 
1152 
1200 
1248 
1296 
1344 
1392 
1440 
1488 
1536 
1591 
1651 
1711 
1733 
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What is claimed is: 
1. A tobacco product comprising cured tobacco material 
made from a tobacco plant comprising a first mutation within 
the coding region of a wild type allele encoding a nicotine 
demethylase having the amino acid sequence of SEQ ID NO: 
2, wherein said first mutation reduces the activity of said 
nicotine demethylase. 
138 
9. The tobacco product according to claim 1, wherein said 
tobacco plant is selected from the group consisting of a Bur-
ley type, a dark type, a flue-cured type, and an Oriental type. 
10. The tobacco product according to claim 1, wherein said 
first mutation results in a substitution at an amino acid residue 
in a position selected from the group consisting of residues 
235,449, 174,410,224,72, 143, and422, wherein said amino 
acid position numbering is according to SEQ ID N0:2. 
2. The tobacco product according to claim 1, wherein said 
tobacco plant further comprises a second mutation within the 
coding region of a wild type allele encoding a nicotine dem-
ethylase having the amino acid sequence of SEQ ID N0:13, 
wherein said second mutation reduces the activity of said 
nicotine demethylase. 
11. The tobacco product according to claim 1, wherein said 
10 
first mutation results in a Tryptophan to stop codon substitu-
tion at amino acid position 422, wherein said amino acid 
position numbering is according to SEQ ID N0:2. 
3. The tobacco product according to claim 1, wherein said 
15 
tobacco material is made by a curing process selected from 
the group consisting of flue curing, air curing, and fire curing. 
12. The tobacco product according to claim 2, wherein said 
first or second mutation is selected from the group consisting 
of a point mutation, a deletion, an insertion, and an inversion. 
13. The tobacco product according to claim 2, wherein said 
second mutation results in a Tryptophan to stop codon sub-
stitution at amino acid position 329, wherein said amino acid 
position numbering is according to SEQ ID NO: 13. 4. The tobacco product according to claim 1, wherein said 
tobacco product is selected from the group consisting of a 
cigar, a cigarette, pipe tobacco, a cigarillo, a non-ventilated or 
vented recess filter cigarette, a dissolving strip, a gum, a 
tablet, snuff, and chewing tobacco. 
14. The tobacco product according to claim 2, wherein said 
20 tobacco plant is homozygous for said first or second mutation, 
or both. 
5. The tobacco product according to claim 1, wherein said 
cured tobacco material comprises a lower level of nornicotine 
or N'-nitrosonornicotine compared to cured tobacco material 25 
made from a tobacco plant comprising said wild type allele. 
15. Cured tobacco material made from a tobacco plant 
comprising a first mutation within the coding region of a wild 
type allele encoding a nicotine demethylase having the amino 
acid sequence of SEQ ID N0:2, wherein said first mutation 
reduces the activity of said nicotine demethylase. 
16. The cured tobacco material according to claim 15, 
wherein said tobacco plant further comprises a second muta-
tion within the coding region of a wild type allele encoding a 
nicotine demethylase having the amino acid sequence of SEQ 
ID NO: 13, wherein said second mutation reduces the activity 
of said nicotine demethylase. 
6. The tobacco product according to claim 1, wherein the 
conversion of nicotine to nornicotine in said cured tobacco 
material is selected from the group consisting of less than 
0.3%, less than 0.5%, less than 0.7%, between 0.1%-0.5%, 30 
between 0.1%-0.4%, between 0.1%-0.7%, and between 
0.1%-1.0%. 
17. The tobacco product according to claim 11, wherein 
said second mutation results in a Tryptophan to stop codon 
35 substitution at amino acid position 329, wherein said amino 
acid position numbering is according to SEQ ID N0:13. 
7. The tobacco product according to claim 1, wherein said 
tobacco plant has a non-converter phenotype and reduced 
nicotine demethylase activity from said first locus. 
8. The tobacco product according to claim 1, wherein said 
tobacco plant is a hybrid. * * * * * 
